Skip to main content

Talk Bio

Actionable Insights Powered by AI

Search This Blog

About

Showing posts with the label investigator-initiated trials

Posts

Third patient death revealed in China's CAR-T and gene therapy trials, spotlighting IIT safety and transparency

on August 18, 2026

CAR-T Cessation of life China Clinical Trials gene editing trial IITs in vivo investigator-initiated trials Lipid Nanoparticles patient safety regulatory oversight RiboX RNA, Circular RXIM002 Systemic Scleroderma

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Archive

October 202618
September 2026237
August 2026213
July 2026197
June 2026189
May 2026217
April 2026257
March 2026233
February 2026175
January 2026261

December 2025151
November 2025147
October 2025222
September 2025190
August 2025161
July 2025130
June 2025159
May 2025174
April 2025191
March 2025205
February 2025198
January 202539

Show more Show less

Tags

United States Food and Drug Administration Clinical Trials Approved Obesity Neoplasms gene therapy Vaccines Glucagon-Like Peptide 1 Phase 3 AstraZeneca

Investments Novartis Roche (company) China acquisition Merck Infrequent Pfizer Eli Lilly Artificial Intelligence Market Pharma layoffs sanofi eli lilly Drug Discovery Biological Factors manufacturing IPO SmithKline Beecham Drug Industry Autoimmune Diseases Drug Development CEO Leadership Cell Therapy Eli restructuring AbbVie Overall Survival Wegovy Novo Nordisk United States Funding Nordisk Non-Small Cell Lung Carcinoma Transplant Registry Unified Management Program drug price Biotechnology Appointments Weight Loss expansion U.S. therapeutic autologous dendritic cells Acquisition COVID19 (disease) CHARGE Syndrome Inhibitor Safety Immunology Muscular Dystrophy, Duchenne Antibody-Drug Conjugates Malignant neoplasm of breast Policy methionine Progression-Free Survival Keytruda Zepbound semaglutide Biogen Centers for Disease Control and Prevention (U.S.) Oral cavity R&D Accelerated Phase 2 Amgen CAR-T Collaboration Dosage Forms Regeneron Sales - occupational activity Partnership Precision Medicine milestone payments Industry Nasdaq Health care facility Alzheimer 's disease Immunotherapy M&A Myers Squibb Solid Neoplasm Clinical Research Drug Approval Malignant neoplasm of lung Antibodies, Bispecific Biopharma Multiple Myeloma AI drug discovery PDUFA financial results Administration occupational activities Biological Science Disciplines Biosimilars EU Effectiveness Moderna Prices Board of Directors Clearance Elevidys Phase 3 Clinical Trials Takeda UK biotech genentech pipeline Changing Gene Modification earnings in vivo rejection Advisory Committees BioNTech Rare Diseases Weight-Loss Agents clinical development innovation Biological Markers Staff ACIP Phase III AI-driven Antibodies Cancer Therapeutic Procedure Clustered Regularly Interspaced Short Palindromic Repeats Gilead RFK Jr. Schizophrenia Series A Trump administration biopharma Growth J&J Johnson & Johnson Myers Phase 2 trial public entity public health medicine (field) Bayer Cardiovascular Diseases Dermatitis, Atopic Financial cost Radiopharmaceuticals trends qualifier Capital Dupixent Metsera Ozempic dosing pembrolizumab 2025 Diabetes Mellitus, Non-Insulin-Dependent Kidney Diseases Medicare clinical trial failure platform research royalties Advice Phase 3 trial Phase 3 trials Programs - Publication Format Revolution Medicines concerns Blackfoot language CDMO Frequency of Responses Malignant neoplasm of prostate Phase 2 Clinical Trials Pricing Transition Mutation US competition optimization production Amyotrophic Lateral Sclerosis Colorectal Carcinoma Gilead Sciences Inflammatory Bowel Diseases Monoclonal Antibodies Pancreatic carcinoma RFK gene RNA Recommendation Series B Study on Hold development aspects squibb venture capital Astellas Cautionary Warning Daiichi Diabetes Health Ivonescimab Licensing Malignant Neoplasms NIH Mouse Pediatric brand name Phase 3 Trial Series Study models acquisitions licensing agreement Alopecia Biosciences Boehringer Ingelheim Deferred MASH NDA Neuroscience discipline Ophthalmology specialty Preventive monitoring RNA, Small Interfering Rheumatoid Arthritis Sankyo daraxonrasib financing characteristics Agonist Endpoints European (ethnic group) Evaluation Hims IGA Glomerulonephritis Medicaid Metabolic Diseases Mutation News [Publication Type] Q3 Senate Small cell carcinoma of lung melanoma orforglipron pharmaceutical manufacturing supply chain tariffs Autoimmune BioMarin CD276 gene Eisai Enhertu Epilepsy Failure (biologic function) Foundayo HHS Insilico Medicine Legal patent Measles-Mumps-Rubella Vaccine Mounjaro Parkinson 's disease milestones net loss tirzepatide Adverse event Antineoplastic Agents Asthma Biotherapeutics CBER Labels (device) Malignant neoplasm of urinary bladder Medical Devices Merck KGaA Multiple Sclerosis Pharmacotherapy Phase 1 (qualifier value) obesity drug pharmaceutical tariffs regulatory safety profile subcutaneous upfront payment 2026 ASCO Burning Mouth Syndrome CAR-T therapy CDER COPD Discontinuation (procedure) Flagship Germany Health Policy Leqembi Multiple Acyl Coenzyme A Dehydrogenase Deficiency Otsuka Proteinuria RNA Interference Robert F. Kennedy SMPX gene TNFRSF19 gene Telemedicine Ulcerative Colitis Wegovy pill cardiometabolic cash runway cost-cutting diagnostics digital health federal government reverse merger submission venture Agentic AI BTK inhibitor Benefit Bio CFO Cells Clinical Clinical Data Combined Commission Discover Drops - Drug Form Duchenne ESR1 gene Eczema Financial savings Hematologic Neoplasms Japan K-ras Oncogene Leukemia, Myelocytic, Acute Malignant neoplasm of stomach Muscular Dystrophy Pauses RNA, Messenger Replimune Response process Risk Severe (severity modifier) Target camizestrant commercialization healthcare technology leadership change ovarian neoplasm patient deaths radioligand therapy regulatory approval trials uniQure Amylin Bispecific Breakthrough Therapy CHMP CagriSema Child Complete Epidermal Growth Factor Receptor Facility (object) HIV Homo sapiens Hypertensive disease Immunotherapy for cancer Ionis Pharmaceuticals Liver diseases Nance-Horan syndrome North Carolina Opdivo PD-L1 Psoriasis Pulmonary Fibrosis RETINITIS PIGMENTOSA 1 Respiratory syncytial virus Spinal Muscular Atrophy Technology alpha 1-Antitrypsin Deficiency alpha 1-antitrypsin discontinued early-stage executive order merger oral SERD royalty strategic alternatives Access Adult Akeso Childhood Vaccines Chronic Spontaneous Urticaria Combined Modality Therapy Confirmation Drug Delivery Systems Drugs, Orphan Efficiency File (record) First line treatment Genomics Heart failure Hidradenitis Suppurativa IL31RA gene Idiopathic Pulmonary Fibrosis Impact food supplement Inflammation LB-102 MFN Mediation Myasthenia Gravis Myasthenic Syndromes, Congenital NVIDIA National Security Phase Revenue Review [Publication Type] Robert F. Kennedy Jr. Sandoz Small Molecule T-cell engager TrumpRx Ultragenyx White House cellular targeting direct-to-consumer drug safety immuno-oncology medtech portfolio ATTR-CM Alzheimer 's Antibiotics Antisense Oligonucleotides BARDA Blood - brain barrier anatomy Board appointment Cancer Research Chronic Kidney Diseases Chronic disease Cystic Fibrosis Diabetes Mellitus, Insulin-Dependent Donald Trump Dosage Eylea Generic Drugs Hallucinogens In complete remission Indonesian language Johnson and Johnson Lenacapavir Machine Learning Makary Mucopolysaccharidosis II Myeloid Leukemia, Chronic Narcolepsy Neurodegenerative Disorders PCSK9 inhibitor PhRMA Priority Review Psilocybin Regenxbio Roivant Series B funding Series C Surgical aspects Surgical construction Tavneos Thyroid associated opthalmopathies Vaccine Safety Vanda Pharmaceuticals Veradermics Weight maintenance regimen Withdraw (activity) approvals biobucks biomanufacturing drugmakers erbB-2 Receptor generative AI inhibitors mental health nivolumab partnerships patent cliff precision oncology surge treatment-resistant depression AAVS1 gene AMT-130 Alkermes Antipsychotic Agents Application procedure Automation Bavarian Nordic Biomechanical compliance Budgets Capricor Therapeutics Contract agreement Detection Eikon Elderly (population group) Evidence Exit HER2-negative HIV prevention Huntington 's disease Identifier Influenza LDL-C Manufacture Manufacturing Facilities Nation Neurology speciality PFS Peptides Pharmaceutical Services Phase 1b Placebos Precision - temporal Product containing glucagon-like peptide 1 receptor agonist (product) Progressive Pulmonary arterial hypertension RNA Editing Retirement Scientific Advisory Board Series B financing Stock Surge Toxicity aspects biotech startups cash position corporate deramiocel lawsuit mRNA flu oncology pipeline primary endpoint private equity resignation retatrutide shareholder targets Achondroplasia Alnylam Anemia, Sickle Cell Angioedemas, Hereditary Antagonist muscle action Attitude Bankruptcy Big Pharma Biotech Layoffs Boehringer Chief Medical Officer Chronic multifocal osteomyelitis Complete Response Letter Conditional Congress (U.S. Legislature) Contraceptives, Oral Depressive disorder ER-positive ESMO Exelixis Forbion Generalized IPOs Imfinzi Incyte Infant Inflation Reduction Act Injury of liver Insmed Insulin Intellia Ipsen J.P. Morgan Healthcare Conference JPM26 Jazz LDL Cholesterol Lipoproteins Letter [Publication Type] Marty Makary Metastatic castration-resistant prostate cancer Nuvalent ORR OpenAI PREP gene Partner in relationship Personalized Phase I Clinical Trials Polycythemia Prader-Willi Syndrome Prasad Presenile dementia RNA therapeutics Response Letter Rinvoq Screening for cancer Sectioning technique Series D Servier Shakeup SpringWorks Supplement Teva Validation acute analysts aspects of adverse effects biology (field) biotech industry cancer drugs cardiometabolic diseases exophthalmos producing substance giredestrant launch manufacturing issues private placement revenue growth stocks strategic collaboration trastuzumab upfront workforce reduction ADCs Abivax Adangme language Aktis Amlitelimab Argenx Atrial Fibrillation Avidity Biosciences Billion Biotech IPOs BridgeBio CLL CNPV Cardiovascular system Cessation of life Childhood Chinese Language Chronic Lymphocytic Leukemia Cobenfy DNA Integration Diffuse Large B-Cell Lymphoma Disease Outbreaks Drug Regulations Enliven Therapeutics Europe Event Extension Fast Track Galleri Gardasil Glycogen storage disease type II Glycosylated hemoglobin A Head Hepatitis B Hereditary Diseases Hetlioz Hong Kong Illumina Inflammatory disorder Injection of therapeutic agent Liquid Biopsy Lupus Vulgaris MAHA Macular edema due to diabetes mellitus Malignant neoplasm of endometrium Menopause Migraine Disorders N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide New Jersey PAH Patient Death Pelacarsen Phase 1 trial Projections and Predictions RMAT Relapsing course Remote Seizures Seqirus Shanghai Tagrisso Triglycerides Trump tariffs Tubulis UX111 VK2735 Vascular Endothelial Growth Factor A Vinay Prasad Wave Life Sciences Zealand Pharma annual asset assets bidding war deals delays deruxtecan equity executive appointments factor IX first generics genetic medicines immunotherapeutics interleukin-6 jet lag disorder manager monthly oral semaglutide patent infringement pharmaceutical innovation pilot program real-world sNDA shionogi shipment small-cell lung cancer sonelokimab startup strategic uridine triacetate ADC AI platform AI-enabled AI-powered Advanced Melanoma Agencies Alumis Anemia Anthropic Apellis Autistic Disorder Biohaven Biomedicines Biosecure Act Brain Neoplasms CD3 Antigens CNS disorder California Camzyos Canada Capital Management Cerebrovascular accident Chief Chief Financial Officer Crohn 's disease DMD Decision Denali Disorder of eye Drug Prescriptions Fund Raising GLP-1 receptor GLP-1/GIP GZMH gene Genmab Geographic Atrophy Guanosine Monophosphate HPV vaccine Healthy Heather Flick Melanson Hot flushes Hyperphagia Immunovant Impaired Import India Indirect Infantile Severe Myoclonic Epilepsy Influenza virus vaccine Innovent Biologics Kelonia Therapeutics Leerink Partners Legend Biotech Leukemia License LillyDirect Liver Failure, Acute Lp(a ) Lundbeck Lupus Erythematosus, Systemic Lymphoma MHRA Maintenance Meeting Mental deterioration Midomafetamine MoonLake Most-Favored-Nation Muscular Dystrophy, Facioscapulohumeral Neoplasm, Residual Nerve Degeneration Neuroinflammation Nitroglycerin/Sodium Citrate/Ethanol Solution Opioids PD-1/VEGF Padcev Pathology Paul Hudson Performance Phase 1b trial Phase 3 clinical trial Pioneering Post-Hoc Live Post-Traumatic Stress Disorder Prescription procedure President brand of dental material Protac RGX-121 Reaction Regenerative Medicine Regulation Retinitis Pigmentosa Secretary Sentiment Skyrizi Statistical Significance T-Lymphocyte TIGIT gene TYK2 gene Talzenna Tecentriq Tolebrutinib Translucent Trodelvy Urinary tract infection Window (physical object) WuXi AppTec Yeztugo agonists authorization baxdrostat biotech partnerships developability diranersen drug review gedatolisib healthcare AI independent review mRNA Vaccine manufacturability minoxidil molecular glue multi-cancer early detection onshoring perioperative personalized therapies pharmaceutical companies pre-funded remibrutinib reorganization resubmission settlement summit survival valuation vedotin zanzalintinib 3-Methylglutaconic aciduria type 2 340B AACR 2026 ADARx AI models AKTS ALS ALV-100 ALV-200 Acquisition (action) Adolescent (age group) Agreement Altimmune Alveus Therapeutics AnaptysBio Antengene Anticoagulants Artisan Partners Arvinas Ascletis Asymmetric Septal Hypertrophy Attention deficit hyperactivity disorder Australia Autoimmune thrombocytopenia Avalyn B-Lymphocytes BCR-ABL1 BNT327 Biliary Tract Cancer Biologics License Application Blenrep Blindness Bourla Buckham CD19 Antigens CDE CE Mark CEOs CIDRAP COVID CSO CVR Cambridge Cancer Vaccines Cancer of Neck Carcinoma breast stage IV Cardiomyopathies Carvykti Cash Celcuity Clinical Nurse Specialists Co. Communicable Diseases Compass Pathways CordenPharma Cytokinetics CytomX DKK1 gene DOGE Datroway De Novo Deafness Deep molecular response Definium Therapeutics Delaware Department of Health and Dependovirus Disease Progression Disease-Free Survival Ditiocarb DualityBio Durham EGFR-mutated Ebvallo Effect Elamipretide Empaveli Etcamah Event-Free Survival Evotec SE FCGRT gene Fabry Disease Failed GIPR gene Galapagos Generative AI Glioblastoma Gomekli Haisco Halda Therapeutics Halozyme Hannah Anderson Head of US Heart Diseases Heidi Overton Hemoglobin A1c measurement Hengrui Hengrui Pharma Henlius Hypersensitivity Hypertriglyceridemia Hypertrophic Cardiomyopathy Immunization Immunostimulating conjugate (antigen) Increase Inosine Triphosphate J.MD Journavx Jr. Kailera Kardigan Labcorp License Application Licensing Deal Litigation Long-term Longevity Lung diseases MYELODYSPLASTIC SYNDROME Malignant neoplasm of kidney MariTide-like Maziar Mike Doustdar Metabolic Metastasis from malignant neoplasm of colon and/or rectum Misinformation Molecular Response Mucopolysaccharidosis Type IIIA Muscular Dystrophies, Limb-Girdle Myelocytic NALF2 gene NECTIN4 gene NLRP3 inhibitors Nektar Therapeutics Neurocrine NewCo Novavax ODAC PARP1 gene PDCD1 gene Parabilis Medicines Patient access Personnel Selection Phase 2 clinical trial Phase I Physicians Platform Pluvicto Project Protein Degradation, Metabolic Q4 2025 R-Series RIPTAC RVMD Recovery - action Recursion Research Projects Retinal Diseases Rick R. Suarez Rocket SPAC Scholar Rock Science Score Seagen Sibeprenlimab Sotyktu Standard of Care Stem Cell Therapy Stock Decline Subcutaneous Injections Surveys Syfovre TMEM79 gene TROP2 TYK2 inhibitor Trimonthly Triple Negative Breast Neoplasms Twice a day Type B meeting Uncertainty United States Federal Trade Commission VDPHL01 VRBPAC Vaccine Integrity Project Ventyx Biosciences ViiV Healthcare Viking Viral Vector Virginia manufacturing facility Voyxact Vyvgart WDR20 gene Wilmington Delaware Winrevair Worker Zymeworks abbott aldosterone synthase inhibitor amendment asciminib atezolizumab avacopan bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine board shake-up capabilities capital markets chain disruption chronic collaboration termination commercial compounding pharmacies coverage - financial contract dealmaking decision letter decline del-desiran departure - ActRelationshipType digital transformation disbanded drug discounts drug manufacturing drug market enforcement engagers enlicitide enzalutamide financial first-line focal onset seizures functional cure funding grant governance human inhaled therapy license agreement mCRPC mimetics muscle-invasive bladder cancer negotiation obesity pill once-daily oveporexton pandemic preparedness patent settlement phase advance protocol preclinical data protein degrader public health policy radiopharma ras Oncogene recommendation change regulatory submission regulatory uncertainty safety review shareholders single-dose schedule spending stock plunge strategic review targeted therapies tasimelteon tolerability tonlamarsen upadacitinib user fees vaccine schedule venetoclax vera virtual care wet AMD zidesamtinib ziltivekimab 130-nm albumin-bound paclitaxel 2023 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide AACR ABVX AI drug development AI healthcare AI model AI-designed AP01 ARD-101 AbCellera Accelerated Approval Acceleration Acute onset pain Adjuvant Therapy Affordability Agios Alcon Alector Alexion Alternative Androgenetic Alopecia Anktiva Antibody-Drug Apnimed Apogee Therapeutics Arcellx Ascendis Pharma Assembly (construction) Atacicept Audit Committee Aurora Therapeutics AutoInjector Autoimmune hemolytic anemia Automobiles B-Cell Lymphomas BEACON-IPF Bain Capital Beak Beyfortus Biological Assay Blood Coagulation Disorders Board Appointment Body mass index procedure Bovichtus Brazil Breakthrough Therapy Designation Brinsupri CDC CDK4/6 inhibitor CDMOs COMP360 CRLs Capsid Cardiology discipline Carlyle Casgevy Cellares Centessa Pharmaceuticals Cervical Atlas Chief Legal Officer Chronic pain Chugai Clinical Failure Clinical Trial Failures Clinician Commissioner Complete Response Letters Compound Confirmatory Trial Contraceptives Corporate governance Creative Biolabs Cystic Fibrosis Transmembrane Conductance Regulator DNA DT120 ODT Darzalex Data Safety David Samra Deficiency Depletion Depression, Bipolar Dermatomyositis Diabetic Retinopathy Diagnosis Dianthus Therapeutics Diversity Dominance Dry Eye Syndromes Dyslipidemias EBITDA EDNRA gene EHA ELAVL2 gene EMA ENPP1 gene EPI-321 Earendil Labs Early Diagnosis Ecosystem Edema Electra Therapeutics Eli Lilly backing Eliquis Employee Employer Enflonsia Engaged to be married Episodic Express Scripts Family Turdidae (organism) Farxiga FibroGen Frazier Life Sciences Funds Futility GE HealthCare GLP-1/GIP dual agonist GLP-1s Gene Silencing Giovanni Caforio Glaucoma Goldman Sachs Gross (qualifier value) Groups Gubra HER2-mutant Health Planning Hearings Hematologic Tests Hodgkin Disease Hypercholesterolemia Hypertrophic obstructive cardiomyopathy IL33 protein, human IMVT-1402 IRA ITM-11 Imdelltra ImmunityBio Immunogenicity (package insert) InduPro * * Injectables Insurance Interferes with Ira (eukaryote) JPM Jaypirca Jefferies Jemperli KOL Kisunla Lab-in-the-Loop Laboratory Lecanemab Legal Lipid Nanoparticles Liver Liver carcinoma Lonza Lupus Erythematosus, Cutaneous Lupus Nephritis Lutathera Lymphoma, Follicular Lynkuet Lysergic Acid Diethylamide M&A activity MC4R protein, human MCED MET-097i MPS MYOTONIC DYSTROPHY 1 MacroGenics Malaria MapLight Therapeutics Marketing Authorization Medical Research activity Medicare Part D Menin Inhibitor Merck & Co. Mississippi (geographic location) Myasthenia Gravis, Generalized Myocarditis NAMs NYSE Neuromuscular Diseases Neuropsychiatry New New Drug Application Non-Muscle Invasive Bladder Neoplasms Nurix Odyssey Therapeutics Ogsiveo Oligonucleotides Oral Organoids Orphan Drug Designation PANSS PBMs PCSK9 protein, human PD-1xVEGF PIK3CA gene Pediatric Disorder Pennsylvania Peter Marks Phase 1/2 trial Phase 1/2a Phase 2 trials Phase 2b Phase II Piperine Extract (Standardized) Plant seeds Pliant Poly(ADP-ribose) Polymerase Inhibitors Pounds Praxis Precision Medicines Preclinical Prediction Preventive Health Services Primary Biliary Cholangitis Primary Myelofibrosis Prophylactic treatment Proteomics Psoriasis Area and Severity Index Clinical Classification Psychological inhibition Psychotic Disorders Q1 2026 Q2 2025 Q3 2025 Quality R&D pipeline RAS RAS-driven cancers RDEP RNA, Circular ROS1 gene Rakovina Ras Inhibitor Real-world Evidence Recordati Regulatory Affairs Regulatory Setback Renal Cell Carcinoma Reparative closure Repatha Research Infrastructure Research Personnel Respiratory physiology Reversal Rezpeg Rhapsido Robotics Rybrevant SERENA-6 SanegeneBio Security - service Selective Estrogen Receptor Down Regulator Series A financing Series D financing Series E Series F Sharing (Social Behavior) Singapore Small Interfering Sofinnova South Korea Stabilizer - function Stealth BioTherapeutics Stelara Structure Therapeutics Subgroup A Nepoviruses Supernus Pharmaceuticals Supreme Court Suspensions Systemic Scleroderma T-cell engagers TMALIN TNBC TREM2 TSLP gene Tablet Dosage Form Team Terns Tessera Transitory UCB Ultomiris Unresectable VTX3232 VTX958 Vabysmo Vaccination Valneva Vas Narasimhan Vera Therapeutics Vinay Vital capacity Vitiligo Wall Street Journal Welireg Workers Workforce Reduction World Health Organization WuXi Xolair YL201 Ziihera Zolgensma Zorevunersen Zynlonta aficamten alfa alixorexton altretamine/cisplatin/cyclophosphamide protocol anti-IgE anti-TL1A antitrust apitegromab biotech collaboration biotech sector board changes bounce business career business development cabozantinib cardiometabolic disease cetuximab chief of chikungunya vaccine chronic hives clinical endpoints conditions contingent value right court data privacy datasets digital twins docetaxel domestic manufacturing domvanalimab drug acquisition dupilumab eloralintide epigenetic editing epigenetic reprogramming executive leadership expense federal judge first-line therapy guidance cut headquarters high-risk ifinatamab immune-mediated diseases leukemia mRNA cancer measles mechanism pathway mitapivat most-favored-nation pricing muscle preservation neladalkib nervous system disorder non-small-cell lung cancer nrSPMS older oncology partnership orexins pacibekitug patient safety payers pharmaceutical marketing pharmaceutical sales pharmaceutical supply chain platforms plunge proposal - intent protein degraders psychedelic therapy rally ranibizumab rates real-world data real-world evidence regulatory compliance requirements research collaboration reshoring revenue guidance rezpegaldesleukin roxadustat rumors sacituzumab tirumotecan scalability seconds shutdown skipping small molecule therapeutics specialty medicines stock crash strategic restructuring strategic shift succession takeover talks talazoparib tariff threat triple agonist tulisokibart update user fee value-based care vusolimogene oderparepvec women 's health zolucatetide AD109 ADRX AI agents AI biotech AI factory AI protein design AI-designed drug ALK gene AMG ANGPTL3 AP02 ARPA-H ASC30 ASCO26 ASGCT ATR Inhibitor Aardvark Therapeutics Acadia Acelyrin Acute lymphocytic leukemia Adoption AdvanCell Advanced phase Advocacy Age related macular degeneration Agios Pharmaceuticals Alagille Syndrome Albert Alexander Disease Americas Amvuttra Amylin Analog Amyloid Amyloid beta-Peptides Amyloidosis Angelini Pharma Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antiviral Agents Apellis acquisition Apolipoprotein E4 Apolipoproteins B Arcus Arcus Biosciences Arrowhead Pharmaceuticals ArsenalBio AtaiBeckley Atara Ataxia Attruby Avidity Awareness BLA BMN BRUIN BTK Base Editing Bausch + Lomb Baxfendy BeOne Medicines Beam Therapeutics Beijing Bhattacharya Biktarvy Bill Cassidy Bio-Techne BioNeMo BioSpace Biological Availability Biomedical Research Biopharma Sentiment Index Black Populations Blackstone BlueRock Therapeutics Blujepa Braveheart Bio Brepocitinib Burden CBO CDK2 protein, human CDK4/6 inhibitors CELMoD CNP gene COAST CRDMO CRO Caldera Therapeutics Candidiasis, Chronic Mucocutaneous Capacity Caplyta Carboxyamidotriazole Orotate Cardiff Oncology Cardiovascular Agents Cardiovascular event Catalent Indiana Celiac Disease Cell Shuttle Chancery Change, Organizational Charles ChatGPT Chief Commercial Officer Chief Operating Officer Chikungunya Fever Christophe Weber Chronic Obstructive Airway Disease City of Boston Claudin-18 Isoform A2 Clinical Benefit Clinical Decision-Making Clinical Trial Design Clinical action Closed Commercial Managed Care - Pharmacy Benefit Manager Complement Inactivating Agents Complicated Computer Security Concentra Biosciences Congenital Construction worker Conventional (Clear Cell) Renal Cell Carcinoma Cost Savings Crackdown Crinetics CureVac Cylembio DILI DLL3 gene DMPK gene DNA Replication Data Integrity Datopotamab deruxtecan Deal Value Death of child Demand (clinical) Dexcom Diabetes Mellitus Disc Medicine Does speak Drug Formulation Process Drug Shortage Drug withdrawal syndrome Dyne Therapeutics Dystrophin ECCO ENTR-601 Edgewise Therapeutics Emma Walmsley Encephalitis, St. Louis Endometriosis Epicrispr Erasca Erythrocytes European Hematology Association ( Expectations Eye Eye Drops EyePoint Eylea HD FDA-approved Fabhalta Familial chylomicronemia syndrome Fibrodysplasia Ossificans Progressiva Fibromatosis, Aggressive Fierce Flatulence Florida France Freezing Functional Fyodor G-Protein-Coupled Receptors GEP-NETs GLP-1 pill GLP-1/GIP receptor agonist GMP manufacturing Gastric Inhibitory Polypeptide General Meeting Generalized Anxiety Disorder Genome Genome Editing Glycogen Storage Disease Type IIb Gold Standard Childhood Vaccine Gout Suppressants HBr HER2-positive HHS layoffs HLD-0915 HOPE-3 trial HRSA Hansoh Pharma Health Care Reform HealthBench Hearing Hemab Therapeutics Hemophilia A Hengrui Pharmaceuticals Hepatitis D Infection Hims & Hers Holdings Holly Springs Hormone Therapy Humira Hypercholesterolemia, Familial Hyperphosphatemia (disorder) Hypothalamic obesity IDeate-Lung02 IGF1R protein, human IGNYTE IGNYTE trial IMNM IQVIA Iambic Iambic Therapeutics IgA Illinois (geographic location) Imaavy Imcivree Immune Immune Medicines Immunologic Adjuvants Immunome Impaired cognition Improvement Increased Incretins Independence Indication of (contextual qualifier) Induce (action) Inflation Ingelheim Inhibrx InnoCare Interleukin-13 Interleukin-17 International Intrathecal Route of Drug Administration Irish (ethnic group) Isomorphic Labs Ixchiq Jakafi Janus kinase Janus kinase inhibitor Jeffrey Jennifer Doudna KRAS NP_004976.2:p.G12C Kailera Therapeutics Karim Mikhail Kelun-Biotech Kerendia Kinaset Therapeutics Kirin Krazati Kura Oncology Kyle Diamantas Kymera Kyowa Laboratory test finding Late stage Legos Lisata Litifilimab Liver Failure Liver and Intrahepatic Biliary Tract Carcinoma Localized Logistics Luke Miels Lunsumio Lupus Erythematosus Lyme Disease Lymphodepletion Therapy Lytenava MRGPRX2 gene Madrigal Pharmaceuticals Management procedure MariTide Maria Sainz Marty Maryland (geographic location) Massachusetts (geographic location) Massive Mechanism Framework Medical Specialities Medical service Medicus Pharma MeiraGTx Menkes disease Menlo Ventures Mental Depression Merus Metastatic Pancreatic Ductal Adenocarcinoma Metastatic Prostate Carcinoma Microglia Microsoft Midline (qualifier value) Mortality Vital Statistics Motion Sickness Myasthenic Syndromes Myopia Myqorzo NIH Narcolepsy type 1 Nasal Spray Nasdaq KARD National Priority Voucher Neoplasm Metastasis Nephrology Speciality Neuphoria Neuregulins Neurodevelopmental Disorders Neurosecretory Systems Nkarta Non-Insulin-Dependent Novavax 's Novo Nucala Nxera Pharma OLN324 Obefazimod Obesity Drug Odyssey Olezarsen Oncolytics Operative Surgical Procedures Options Oregon (geographic location) Orum Therapeutics Otsuka Pharmaceutical Oura Oura Ring Ouro Medicines PDE3/4 inhibitor PYRUKYND Pain management Parity Partial Personnel Turnover Pet Animal Phage Therapy Pharma Industry Pharmaceutical Group Pharmaceutical merger Pharmacovigilance Pharmacy facility Phase 1/2 data Phase 3 failure Phase IIb Pierre Fabre Pipeline Development Pirtobrutinib PreCheck Precision immunology Pressure- physical agent Primary Prevention Priority Review Voucher Privacy Protein Domain Protein Engineering Protein-tyrosine kinase inhibitor Prothena Pruritus Public Offering Pulmonary Hypertension Pulse Biosciences RAP-219 RAPT REMS RGX-111 RNA Splicing Radiant heater Rani Therapeutics Rapport Therapeutics Rating (action) Recurrent respiratory papillomatosis Reduced RegenXBio Regulatory Action Reimbursement Relapse RemeGen Repertoire Report (document) Respiration Disorders Restrictions Rett Syndrome Revenue Decline Revtorpyk Rexulti Rhythm Pharmaceuticals Richard Pazdur Rocatinlimab Rosnilimab SCN1A gene SK Biopharmaceuticals SLC22A18 gene SLC6A8 Inhibitor RGX-202 SNCG gene STELLAR-303 Samsung Biologics San Diego Sanofi Ventures Sarclisa Saxenda Science of Chemistry Scientific Study Secondary malignant neoplasm of pancreas Secretary Nomination Senate hearing Sentivera Services Shingrix Sleep Apnea Syndromes Sobi South San Francisco Spikevax SpinCo ' Spinal Cord Injuries Spinocerebellar Spinraza Stargardt's disease Stifel Stiff-Person Syndrome Substance Use Disorders Surrogate Suzetrigine Switzerland Synthetic Biology Systemic T-Cell Receptor TERN-701 TNFSF15 gene TUB-040 Taiwan Takeover Targeted Therapy Tecvayli Tempus AI Tepezza Testing Therapeutic immunosuppression Thermo Fisher Thermo Fisher Scientific Tradipitant TransCon Transection (procedure) Treatment Protocols Tremfya TrialBlazer Trump Trump executive order Trump executive order Truqap Tryngolza UAE UPenn Unable to walk (finding) Uncontrolled United Kingdom United States National Institutes of Health UnitedHealth Group Unresponsive to Treatment Uplizna UroGen VAERS VERVE-102 VG-3927 VIKTORIA-1 VX-264 Vascular Diseases Vaxart Venclexta Venous blood sampling Vepdegestrant Vera Verona Verzenio Viking Therapeutics Viridian Vision Vykat XR Vyndamax Vyne WVE-007 Wages Wainua Western patients Winter Park Woman Workforce - population group Xtandi YUVIWEL Zegfrovy Zenas BioPharma Ziftomenib Zilganersen Zurzuvae activism adaptation addiction adulteration advanced breast cancer advanced solid tumors advanced therapies amivantamab antibody engineering asthma drug augmented azacitidine bemdaneprocel benzamide antipsychotic benzamide class bexotegrast binding affinity biomarker testing biopharmaceutical manufacturing biotech acquisition biotech merger biotechs branded drugs brensocatib calcium glucarate cancer care cancer drug development care activity cell renal cell carcinoma centanafadine checkpoint inhibitors childhood vaccine schedule claims clinical AI clinical pipeline clinical remission clinical trial design clinical trial termination commercial strategy companion diagnostic constraints corporate governance ctDNA data integration data manipulation deadline deal decentralized decitabine degrader antibody conjugate degraders deucravacitinib dexamethasone digital pathology direct-to-consumer sales discount divesiran dosed dostarlimab draft guidance drug efficacy drug shortages durability durvalumab election envudeucitinib evolocumab exacerbations exon federal funding federated learning felzartamab fibroblast growth factor 21 fill-finish first-in-human trials gMG gastroesophageal adenocarcinoma gemcitabine genetic data gepotidacin global expansion goal health data healthtech iTeos ianalumab iberdomide ibogaine interleukin-23 investor investors itepekimab language models lawsuits lean-mass liraglutide mRNA Vaccines meeting melanoma drug merger agreement mergers mid-stage trial milvexian multispecific antibodies nPulse navepegritide nerandomilast net sales neurological diseases neurology pipeline nex-z next-generation nivisnebart nomination oHCM obesity trial obinutuzumab omalizumab onvansertib operating profit operational oral peptides oral therapies oral treatment ounce outcomes partnership termination patented drugs patient death patient outcomes payment payments pemvidutide personalized cancer petrelintide pharmaceutical acquisition pharmaceutical litigation pharmaceutical partnership pipeline reduction pirfenidone platinum-resistant point-of-care preclinical programs predictive predictive models premium prepulse inhibition activity prescription drug costs priority review vouchers public trust pumitamig reality rebound recurrence-free survival refusal regorafenib regulatory environment regulatory filings regulatory guidance regulatory science resilience review extension rusfertide ruxolitinib sac-TMT scrutiny second-line treatment seed fund setback setmelanotide sevabertinib sigvotatug vedotin single dose site closures skepticism sonesitatug statutory scheme stock drop strategic partnership strategic partnerships synergies synthetic construct terminations therapeutic areas therapeutic protein ticker travel trial design twice-yearly injection type 2 inflammation unapproved upsized vaccine overhaul valproic acid glucuronide vasomotor symptom webinar wild-type winners zasocitinib zumilokibart 0% 100% 15% 200 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene 6-amino-1-hydroxyhexane-1,1-diphosphonate 75% 8 90% AACR25 AAV Vector AAV9 ABBV-295 ABI-5366 ACR gene ACTN4 wt Allele AERIFY-1 AERIFY-2 AFFINITY DUCHENNE AH 001 AI Platform AI drug design AI health AI platforms AI safety AI skills AI tool AI-enabled care AI-native platform ALK Inhibitor AMD AML ANCA vasculitis ANOPHTHALMIA AND PULMONARY HYPOPLASIA AOC AP306 APG777 APMD APOL1-mediated kidney disease APRIL inhibitor ARCH Venture Partners ARTEMIS-008 ASCVD ATG-201 ATTD ATTO-1310 ATTRv-PN AVLN AWS HealthLake Abeona Abnormality of mitochondrial metabolism Accurate (qualifier) Acromegaly Actinium Actuate Therapeutics Adaptimmune Administration of prophylactic statin Administrative action Adverse effects Advertising (activity) Adverum Biotechnologies Advisory Panel Afimetoran Age Aging AgomAb Alameda Headquarters Albert Bourla Alcohol Use Disorder Alcohol abuse Aldeyra Alfasigma Alkeus Allo-Glue platform Allogene Allogeneic Alteogen Alvotech Alzheimer Alzheimer 's psychosis Amazona Ambros Therapeutics Ambulatory Care Facilities Amgen 's Amgen settlement Amicus Therapeutics Amitiza Amplia Amylyx AnHorn Medicines Analgesics Analgesics, Non-Narcotic Angelman Syndrome Anti-Inflammatory Agents Anti-OX40 Hexavalent Agonist Antibody INBRX-106 Antibody Therapy Antifungal Agents Antimicrobial Resistance Antistreptolysin O Anxiety Disorders Appia Bio Apple Watch Apply Arbutus Arenaria <Aves> Arrowhead Arthritis, Psoriatic Arthrosi AsedaSciences Asia, Southeastern Atopic Attovia Therapeutics Aurinia Autoantibodies Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes Avadel Pharmaceuticals Availability of Aves AviadoBio Avlayah Awards Awiqli Axpaxli Ayrmid Azafaros B-Well trials B-cell depletion BCG-Unresponsive BGI BGM0504 BHV-7000 BII BIIB080 BIOSECURE BMS BNC210 BNT122 BPC 157 BPL-003 BPSI Barzolvolimab Bassas da India Batoclimab Bay Area Be6A Becker Muscular Dystrophy Behavior Bepirovirsen Big Beautiful Bill Bill Anderson Bimzelx Bio-Rad BioAge BioArctic BioCapital BioNTech 's BioXcel Therapeutics Biochemical Pathway Biopharma Advisory Board Biopharma layoffs Biosafety Bioscience Biotech Innovation Black Box Warning Blackstone Life Sciences Blackwell GPUs Blood Pressure Bloomington Indiana Bluebird Bio Bone Diseases Boston Scientific Boundless Bio Brain Delivery Module Brain-Computer Interfaces Brainomix Breakout Ventures BrightGene Broad Institute Bronchiectasis Bruton 's tyrosine kinase inhibitor Buyout CALD CAN-2409 CD19xCD3 CD228V CD388 CD79a antigen CE (Rh group) CELIA CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS CERVINO CGM CHF CLASI-A CLL-313 CLL-322 CLN-978 CMPX CMS COMPANION-002 CORALreef CORALreef AddOn COVID-19 Vaccines CPOX gene CREM gene CRF2 receptor CRL CROI CRPS-1 CRSwNP CSU CT-996 CTNNA2 gene CTSC gene CTX310 CUE-221 CUTX-101 Cadence OTC Calquence Cancer Detection Candel Therapeutics Capillary Leak Syndrome Capital Partners Capricor Capricor Deramiocel Cardamyst Cardiovascular Risk Cartesian Cartography Biosciences Case (situation) Cash Crunch Catalent Cataplexy Cavazzoni Celea Therapeutics Cell Culture Techniques Cell Differentiation process Cell Engineering CellCentric Celldex Celltrion Center for Drug Evaluation Centers for Medicare & Medicaid Services Central Core Myopathy (disorder) Cerebral Edema Chai Discovery Chairperson Challenge Charles River Laboratories Chickenpox Chief Business Officer Chief Product Officer Chief Technology Officer Chimeric Antigen Receptor T-Cell Therapy China-based Chinese biotech Cholangiocarcinoma Cholestasis-edema syndrome, Norwegian type Cholestatic pruritus Chorionic Villi Sampling Chris Boerner Chris Klomp Chronic cough Chronic inflammatory disorder Chronic low back pain Chronic neutropenia Chronic sinusitis Cidara Therapeutics Cityblock Health Clarity Claude ClearNote Health Clinical Advisory Board Clinical Decision Support Clinical Oncology Clinical Services Cogent Biosciences Colorado Columvi Commission approval Commissioner 's National Priority Voucher Communication Communications Media Community Company Split Comparative Efficacy Comparison Compass Therapeutics Complex Regional Pain Syndromes Compounders Comprehensive Conferences Consultation Consumer Safety Contineum Therapeutics Continuous Glucose Monitoring System Continuous glucose monitoring Contract Development Contract Research Organization Corcept Corcept Therapeutics Cosentyx Country Covid vaccine Crohn 's & Colitis Congress Crystalys Therapeutics Cue Biopharma Cullinan Cullinan Therapeutics Curevo Curium Customer Cutaneous Cylinder Health DB-OTO DCD gene DCLRE1C gene DEI DEL-AI DELIVER (veterinary product) DESTINY-Lung04 DISC-3405 DNA Methylation DNA medicines DOJ DOR/ISL DPP1 inhibitor DTC DUPAC DURAVYU DUX4 protein, human Daily Dapiglutide Darovasertib Darzalex Faspro Data Analysis Data Quality Daytime Somnolence Deep Apple DeepHealth Deerfield Management Degenerative polyarthritis Degrader Delaware Court Deloitte report Denmark Dental Plaque Dentatorubral-Pallidoluysian Atrophy Depression Depression, Postpartum Deramiocel Dermatitis Dermatologic disorders Dermatology field Diabetes Therapy Diagnostic Imaging Dilution technique Diphtheria-Tetanus-Pertussis Vaccine Discipline of Nuclear Medicine Disease remission Donanemab Dopaminergic Neurons Dordaviprone Dr. Droughts Drug Approval Process Drug Costs Drug Design Drug Enforcement Administration Drug Pricing Program Duke Clinical Research Institute Dwarfism EASI EASI-75 EIK1005 EMBARK trial EMMI ENV-294 EPS EQT ES-SCLC ESMO Congress ETX101 EU Approval EV-304 EVO756 EZH2 protein, human Economics Electroencephalography Electromechanical dissociation Electrophysiology (science) Electroporation Elicio Therapeutics Eligibility Determination Elivaldogene autotemcel Elon EloraTZP Elraglusib Emergency Contraception Emergent BioSolutions Employment Termination Enchant v3 Endo England Enhance (action) Entrada Enveda Environment Envisagenics Enzymes Eosinophilic esophagitis Epcoritamab Epigenomics Epilepsies, Partial Eplontersen Escena Escherichia coli Esperion Esthetics (discipline) Etavopivat European Commission European Medicines Agency Evaluation procedure Evernorth Evidenced Evommune Evotec Excessive (qualifier value) Exdensur Executive Chairman Exercise Experimental drug FAYUVI FIBRONEER-ILD FLAURA2 trial FLUm3HA.b-3NA FOXD3 gene FY2025 Factor XI Factor XIa inhibitor Fair Language Proficiency False Claims Act Familial mitral valve prolapse Fast Track designation Favored FcRn Federal Circuit Feedback - system communication Fertility Agents Fertilization in Vitro Fibromyalgia Fibrosis, Liver Fibrous histiocytoma of tendon sheath Fierce AI Innovation Awards Fierce Life Sciences Filspari Financial Forecast Revision Focal Food Safety Force Fortress Forzinity Foster City Fosun Pharma Foundations Fragile X Syndrome Fraud Friday Friedreich 's ataxia Fujifilm Fulcrum Therapeutics GABA Modulators GB-0895 GDF8 protein, human GIVE program GLP-1/GLP-2 GLP-1/glucagon GS-1720 GS-4182 GSPT1 gene Gaithersburg Galleri test Gan & Lee Pharmaceuticals Garijo Gastrointestinal Stromal Tumors Gazyva Gemini of Coiled Bodies Gender Gene Expression Gene Mutation Generate Generation Park Generic Competition Genetic Medicine Genetic Profile Genrix Bio George Tidmarsh Goldcrest Gonorrhea GoodRx Google Google Cloud Govorestat Grail Gram-negative bacteria Granulovirus Guidelines HARBOR trial HARMONi trial HARMONi-GI1 HELP Committee HER2-negative breast cancer HER2-positive carcinoma of breast HERO trial HFpEF HIBISCUS trial HIV sales HKEX HLX316 HM17321 HOPE-3 HR+ HR-positive HR-positive/HER2-negative breast cancer HRS-1596 HRS-5346 HYMPAVZI Hallopeau-Siemens Disease Hand Strength Hanmi Harbour BioMed Hazard Ratio Health Canada Health Care Market Health Personnel Health Services Research Health Systems Agencies Health agencies Healthcare AI Heart Helicon peptide platform Hemagglutinin Hematology (discipline) Hemlibra Hepatitis B, Chronic Hepcidin Hereditary Hereditary Coproporphyria Hernexeos Herpes zoster disease Heterotopic Ossification High High-Throughput Nucleotide Sequencing Highest Hikma Pharmaceuticals Hillhouse Investment Management Hillsboro Hinge Health Holter Electrocardiography Home environment Hong Kong IPO Hong Kong NDA Horizon Hospitalization Hospitals House mice Hua Medicine Hyderabad Hyperlipidemia Hypoglycemia Hypoimmune Technology Hypoparathyroidism Hypophosphatasia I-DXd IBI343 ICOTYDE IGFBP7 gene II ISEMBYLD IZERVAY Ibex Medical Analytics Ibrance Ideaya Biosciences Idorsia IgG4-Related Disease Igalmi Imbruvica Immune System Diseases Immune Tolerance Immune response ImmuneOnco Immuneering Immunization Schedule Immunoglobulin IgG4 Immunology pipeline Immunoregulation Imunon Inavolisib Indiana Individual Adjustment Individualized Indivior Infant, Newborn Infantile Neuroaxonal Dystrophy Infections of musculoskeletal system Infinimmune Infusion procedures Ingram Inluriyo Inobrodib Insitro Inspection (procedure) Intact Intellectual Property Intelligence Interim Interim Analysis Interoperability Interval Intra-Cellular Therapies Invasive Invasive meningococcal disease Inventiva Investigational New Drugs Investor Reaction Io satellite Ionis Isomorphous Israeli (population group) Itovebi J&J 's JCR JNJ-4496 Janssen Japanese language Jascayd Jay Jay Bhattacharya Jeito Capital Johns Jon Congleton Jorna Judge July KCNT1 gene KEYNOTE-B15 KGaA KOL Bulletin KOMET-001 KRAS KRP KRP-M223 KRRO-110 KRSA-028 KRYSTAL-1 KT-621 KYV-101 Kai Beckmann KalVista Kartos Therapeutics Karyopharm Therapeutics Kennedy Kevin Tang Kezar Life Sciences Kidney Failure, Acute Kidney Failure, Chronic King Kisqali Kissei Kodiak Sciences Komodo Health Korro Bio Korsana Biosciences Kresladi Kuva Labs Kymab Kyorin Kyowa Kirin Kyverna Kyverna Therapeutics LAVA LB2501 LBCL LBRX LEAP LGBTQ+ LUGANO LUMRYZ LYT 100 Languages Lantheus Lars Fruergaard Jørgensen Latigo Latozinemab Laurie Stelzer Lawrenceville Lawyer (occupation) Lazcluze Leadership Transition Lean Mass Lenvima Leukocyte adhesion deficiency type 1 LifeMD Lifting Lightning Step Lila Sciences Lilly Gateway Labs Lilly TuneLab Lilly collaboration Lilly partnership Limited (extensiveness) LimmaTech Linerixibat Linsitinib Lipoprotein(a ) Livdelzi London Long Intergenic Non-Protein Coding RNA Lumakras Lung-01 Lutetium-177 Lux Capital Lysosomal Storage Diseases M&A strategy M&A surge MADRS score MAGNITUDE trial MASP-3 Inhibitor MBX Biosciences MEK MEMO1 gene MET-233i MGI MIBC MOONLIGHT-1 MPLT MRD MRD-negative MRT-6160 MSTAR Mabwell Major Depressive Disorder Malignant neoplasm of anus Mallinckrodt MannKind Mantle cell lymphoma MassBio Massachusetts biotech Mayo Clinic Measures MedKey Median Technologies Medical Imaging Medical Records Medicare drug-price negotiation Mehmet Mendra Meningococcal vaccine Mental Recall Mereo BioPharma Mesenchymal Stem Cells Metabolic Syndrome X Mexico Michael Davis Microbicides Microbiome Microgravity Miebo Mike Doustdar Milestone Miller Dieker syndrome MindMaze Mineralys Mint - sweet Mirum Pharmaceuticals Mismatch Repair Deficiency ModeX Molecular Glue Degrader Molecular Imaging Monitoring Board Monte Rosa Therapeutics Montgomery-Asberg Depression Rating Scale Questionnaire Montgomery-Åsberg Depression Rating Scale Monthly (qualifier value) Morning After Pill Mother (person) Motor function (observable entity) Mozafancogene Autotemcel Multiple Sulfatase Deficiency Disease Musk secretion from Musk Deer Mycoses Myeloid cell engager MyoKardia Myocardial Infarction Myotonic Dystrophy NAION NBD1 NDSRI NEFL gene NEJM NEREUS NPM1 Nasdaq ATTO Nasdaq EIKN Nasdaq PBLS Nasopharyngeal carcinoma National Security Commission Navsunli Negative NervGen Pharma Neuraminidase Neurimmune Neurodegeneration Due To Cerebral Folate Transport Deficiency Neuroendocrine Tumors Neurofibromatosis 1 Neurostimulation procedures of spinal cord tissue New Approach Methods New-onset refractory status epilepticus NewAmsterdam Pharma NewLimit Newleos Nimbus Therapeutics Nipocalimab Norovirus Note (document) Novo Nordisk Foundation OBBBA OPKO Health OPTIMA trial OTOF gene OX40 agonist OXTR gene Obesity care ObesityWeek 2025 Obexelimab Obicetrapib Obstetric Delivery Obstructed Ocrevus Ocular Toxicity Office Ohtuvayre OliX Ollin Ollin Biosciences Omeros On-Demand Webinars Oncologic Drugs Advisory Committee Oncology drugs Opdualag Open OpenFold Consortium OpenFold3 Opinions Optogenetics Oral Medicine Oral region OrbiMed Orca Bio Orexin Receptor Agonist Organization administrative structures Organon Orionis Biosciences Ornithine carbamoyltransferase deficiency Orthopedics Orzeyful Overweight Oxnimbi PCAC PD-1/VEGF bispecific antibody PD-L1-positive PD-L1xVEGF PF-08046031 PF-08653944 PHD1/2 inhibitor PIK3CA mutation PIPE-307 PLK1 gene PLN-101095 PLRX PM359 PP405 PROBODY PROTEUS trial PTC518 PWS Palvella Therapeutics Pancreatitis, Acute Panorama trial Papzimeos Paragon Therapeutics Parkinson Disease Paroxysmal nocturnal hemoglobinuria Paroxysmal supraventricular tachycardia Parts per million (qualifier value) Patent extension PathAI Pathos AI Paul Offit Paulo Fontoura Pemphigus Vulgaris Penmenvy Peptide Biosynthesis Pericardial effusion Personalized cancer care Persons Petosemtamab Pharma AI Pharmaceutical Research Phase 2a trial Phase II B Trial Phase IIa Phenylketonurias Philadelphia Philips Phobia, Social Physical and emotional exhaustion state Pick Disease of the Brain Pilot Pipeline Progress Pivot Device Plexiform Pliant Therapeutics Podnosis Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Poolbeg Population Health Partners Positive Post-transplant lymphoproliferative disorder Poster Postpartum Practice Experience Pre-Clinical Model Precigen Prediabetes syndrome Predictive analytics Prefilled Syringe Pregnant Women Presentation Preventive Care Previous Primary Health Care Primary Hypersomnia Primary amyloidosis Prime Medicine Principles Priovant Private Room ProFound Therapeutics Problem ProfoundBio Progranulins Project NextGen Promotion (action) Protection Protein Degradation Protein Tyrosine Kinase Proteins Protocols documentation Prussia Public Preparedness Pulmonary Q1 2025 Q2 2026 QIAGEN Qualitative form Quality of life Quest Diagnostics Qyuns Therapeutics R&D setbacks R1 Therapeutics RAS inhibitors RBPMS protein, human RC148 RECONNECT REMODEL-1 REMODEL-2 REZILIENT3 RNA medicine RNAi medicines RP-A501 RSV RTW RadNet Rasonque Reactive Hemophagocytic Syndrome Realigning Records Recruitment Recurrence Recursion Pharmaceuticals Regulatory T-Lymphocytes Relocation of home or business Renal function Rentosertib Republican Republicans Research Projects, R-Series Resistance (Psychotherapeutic) Resistant hypertensive disorder Response Letters Retevmo Retina Retinal Vein Occlusion Reunion Revenue Upgrade Rezdiffra Rezpegaldesleukin Rhode Island Rigel Pharmaceuticals Rilzabrutinib Rising Risk Management River Laboratories Robert Langer Rogaine Romvimza Rybelsus Rytelo SA030 SABCS SANRECO SAT-3247 SCTX SENS-601 SERENA-4 SERENA-6 trial SG&A SIMTRIYO SION-719 SLL SOLSTICE SOPHiA GENETICS SPN-820 SPR2015 SPS STAR-221 STARGLO STAT6 degrader STP-100 SURF302 SURVEY.ALSFRSR SV Health Investors SVP SYMPHONY-1 trial Sail Biomedicines Salts Samsung Saphnelo Sarcoidosis Satellos Scancell Scemblix Schrödinger SciBrunch Therapeutics Scott Gottlieb Seaport Therapeutics Sebetralstat Section 232 Self Confidence Senate Finance Committee Senate HELP Committee Senior - Suffix Sense of identity (observable entity) Sentynl Sentynl Therapeutics September 23 Septerna Serapha Bio Series C financing Sernova Serplulimab Shockwave Medical Short Bowel Syndrome Sidewinder Therapeutics SigVie-002 Silence Therapeutics Simcere Simcere Zaiming Sino Biopharmaceutical Sionna Sironax Site SkySTAR platform Skyhawk Skysona Slate Medicines Sleep Sleep Apnea, Obstructive Sleep Disorders Sleep medicine specialist Sleeplessness Sling Therapeutics Social Welfare Social stigmata Sodium Channel Blockers Software as a Medical Device Soleno Spain Spero Therapeutics Spinout Squamous cell carcinoma of the head and neck St. Louis Stabilization Stable status Standard (qualifier) Standard BioTools Star Therapeutics Statistical Analysis Plan Steroids Stewardship Stipple Bio Stivarga Stock Crash Stock exchange Stoke Therapeutics Subcutaneous Keytruda Summer Sun Pharma Sunwave Super Bowl ad Sustained-release Mitomycin C Hydrogel Formulation UGN-102 Svalbard Swiss Symbravo Synlogic Synthetic Lethality Syringes TAK-861 TALAPRO-2 TAR 200 TB-500 TCE TERN-601 TJ Biopharma TMPRSS6 gene TNFRSF4 gene TP53 gene TPTE2 gene TRANSCRIPTION FACTOR TRUTAKNA TSND-201 TSRA-196 TTR gene TTR wt Allele TUB-030 Tabelecleucel Taiho Tango Therapeutics Targeted Protein Degradation Tarlatamab Tazverik Tecartus Tecelra Technology, Health Care Teladoc Television Telix Telix Pharmaceuticals Tenaya Therapeutics Tender Tension Terray Therapeutics Tetradecanoylphorbol Acetate Texas Thalassemia Theranostics Theravance Biopharma Thrive TimeLine Fluoride Releasing Resin Tissue damage Tozorakimab Transaction Transcend Therapeutics Transfer RNA Translarna Travere Treating Treeline Tregs Trial Termination Trikafta Trontinemab Trulicity Trump drug pricing Trump loyalists Trump vaccine schedule Tuberculosis TuneLab Type 2 Type C meeting Tyra Biosciences Tyruko Tysabri U.S.-China UB-221 UBT251 UGX-202 US tariffs USPSTF UTP-monosaccharide-1-phosphate uridylyltransferase activity Ugur Sahin Union United States Health Resources and Services Administration United Therapeutics Universities University of Pittsburgh Unnatural Products Unsolicited Adverse Event Utah VANQUISH-1 VESALIUS-CV VESPER-3 VGA039 VISIONARY VISTA trial VTCN1 gene Vaccine Company Vaccine Development Vaccines, Combined Valo Health Varda Space Industries Variant Variant Bio Varseta-M Ventus Therapeutics Veppanu Verona Pharma Viable View View Bora Vigil Vimkunya Vir Biotechnology Vital capacity test Vomiting Voxzogo Vykat WEE1 gene WVE-006 Wakefulness Walmart Pharmacy Wayrilz Wellcovorin Whooping respiration Wnt Signaling Pathway Wugen X-linked retinitis pigmentosa XLRP Xiidra Xocova Xpovio YB-101 Yale Yarrow Bioscience Yescarta Ying Huang YolTech Ypsomed Yupelri ZEUS trial ZEVASKYN ZYCUBO Zag Bio Zai Lab Zaltenibart Zealand Zenkuda Zepzelca Zimmer Biomet Zydus Lifesciences Zynyz abemaciclib access program acute liver injury acute pain treatment ad campaign adagrasib admilparant aflibercept agentic AI algorithm all-stock alpha therapies alpha-Synuclein amisulpride ampreloxetine amycretin analytics anaphylaxis anti-TSHR antibody anti-fibrotic anti-seizure medication anti-tumor activity antiarrhythmic peptide antibody libraries antitrust lawsuit apatinib appeal at-home treatment at-risk atebimetinib atogepant autogene autoinjectors avacincaptad belimumab belrestotug benzamide bevacizumab bexobrutideg bezuclastinib bile duct syndrome billion biopharma executives biopharma financing biopharmaceutical company biopharmaceutical development biopharmaceutical industry biopharmaceutical innovation bioprocessing biotech closures biotech downturn biotech partnership biotech startup bispecific ADCs bispecifics black box black market blockbuster drugs blood sugar control blood thinner board chair bone health bota-vec boxed bretisilocin brexpiprazole briquilimab buyback cUHDRS campus cancellation cancer discovery cancer pipeline capitalization capsule (pharmacologic) carbetocin cardiometabolic health cardiovascular pipeline cell line development cell therapy manufacturing central venous catheter (CVC) sets cevumeran charge amounts checkpoint inhibitor cholesterol chronic hand eczema cibotercept civorebrutinib claseprubart class action clinical operations clinical outcomes clinical program clinical strategy clinical-stage clinical-stage assets clinical-stage companies cold chain logistics companion diagnostics competitiveness concept confirmation contingent value rights continuous glucose monitor contract manufacturing control act - information corneal fluorescein staining corporate strategy cost management cost-cutting measures cross-border cytotoxic T-lymphocyte antigen 4 dabogratinib danuglipron darlifarnib day dazucorilant de novo design debt debut decision delay denosumab departures diabetes care diabetes drug direct-to-employer direct-to-patient disease prevention disease treatments disruption divestment dividend dolutegravir domestic drug manufacturing domestic partnerships dorzagliatin dotinurad drug applications drug development halt drug launches drug pipeline drug rejection drug response drug spending drug-resistant epilepsy dry AMD dual-targeting CAR-T early development economic impact elecoglipron emugrobart engine enrollment entry - ActRelationshipCheckpoint etentamig etripamil ex vivo executive appointment executive promotions executive transition executives exemptions expert expertise experts eyonis fast-track approval fenebrutinib fentanyl crisis financial performance firings first-in-class first-in-human framework gains gamgertamig gene targets generic pharmaceuticals gildeuretinol glucagon glucokinase activator growth outlook growth strategy hair regrowth health disparity healthcare investment heart health hemoglobin response hepcidin high-risk groups high-throughput screening human antibody human papillomavirus hydrocortisone iRhythm icotrokinra imeroprubart imlunestrant impairment charges import alert improvements incretin drugs inebilizumab infigratinib infringement injunction innovative medicines interim interleukin-12 intismeran investing ipsoprubart islatravir islet isononanoyl oxybenzene sulfonate issues lab space laru-zova leader leadership appointments leadership shakeup leases lentiviral vector lenvatinib leucovorin lexicon liability lifitegrast listings liver transaminase liver-targeted RNAi lobbying loncastuximab tesirine long-acting long-acting injectables lonvo-z lorigerlimab losses low-grade mCRC mRNA manufacturing mRNA therapies macrocyclic peptides maintenance trial manufacturers manufacturing campus manufacturing capacity manufacturing deficiencies masetecan mass layoffs medical AI medical technology meloxicam merger talks metabolic health methodologies methylone microenvironment mifepristone military companies mirdametinib mitomycin mo-rez mocertatug molecular glue degraders molecular glues molecular residual disease multimodal AI namilumab nanoparticle delivery narmafotinib net income next-generation biologics next-generation sequencing non-hormonal treatment non-opioid pain drugs off-target on-body injector once-monthly once-weekly ophthalmic preparation oral drug oral drugs oral obesity drugs oral small molecule oral therapy overcapacity p300/CBP inhibitor palbociclib patent cliffs patent litigation patient enrollment pegcetacoplan pegol pegozafermin perfluorohexyl-octan persevERA personal reasons pharma innovation pharma partnerships pharma revenue pharmaceutical commercialization pharmaceutical competition pharmaceutical manufacturers pharmaceutical negotiations pharmaceutical partnerships pharmaceutical regulation pipeline cutbacks pipeline focus pipeline pivot pipeline prioritization pipeline review pituitary adenylate cyclase activating polypeptide placebo-controlled trials platform technology designation poly-N-4-vinylbenzyllactonamide portfolio strategy povorcitinib precision cancer preclinical pipeline preclinical research presbyopia prescription discounts price cut prime editing probationary workers product profit guidance protein design protein design AI protocol design psychedelic medicine public hearing quality management questions rap-cel real-time monitoring rebisufligene recipients recombinase reconciliation recurrence prevention reforms registrational development regulatory challenges regulatory decisions regulatory filing regulatory hurdles regulatory policy regulatory reform regulatory review regulatory setback regulatory strategy relacorilant relapsed/refractory multiple myeloma remigromig removal technique renal response repeal reproductive healthcare reproxalap research funding research study reshuffle rezetecan ribupatide risk mitigation risk-benefit analysis risvutatug rezetecan rizatriptan sales growth search - EntityNameUse securities serono sertraline setbacks skinny label small molecule therapies small molecule therapy solbinsiran sotorasib sparsentan speed spindle orientation checkpoint stake startups stop work strategic brands strategic realignment subcutaneous delivery subcutaneous formulation submissions subscription program sunvozertinib supply chain resilience supply chains survodutide sustainability systemic treatment tafamidis takeover taletrectinib tarcocimab tedromer tariff exemption tazemetostat tebapivat tenosynovial teriflunomide therapeutic antibodies thimerosal third quarter 2025 tividenofusp topline topotecan tourmaline tovecimig treatment failure treprostinil palmitil inhalation powder trial failure trispecific T-cell engager trispecific antibody troriluzole tumor targeting tumor-activated tumor-selective antigens ultra-rare diseases underwriters underwritten upper limb function ustekinumab uveal melanoma vaccine access vaccine deaths vaccine developers vaccine panel vaccine politics vaccine sales varsetatug vatiquinone velinotamig vepdegestrant viral suppression virtual screening volrustomig vomiting prevention vormatrigine vosoritide vote voucher program warning letters webinars weight-loss weight-loss pill wet age-related macular degeneration working capital wound care xRNA zimberelimab zimislecel zipalertinib zoldonrasib zongertinib (3beta * * European Life Sciences Coalition * * Global Expansion * * * * Riad Mishlawi * * * * Vivek Ramaswamy * * * * atopic diseases * * * * functional cell 1-methyl-1-piperidinomethane sulfonate 10 mg 15B 15th 1964 1L pancreatic cancer 2,2,6,6-tetramethyl-4-piperidine-N-oxide 2-aminoethylmethyl sulfone 2/3 20% 2024 2026-2035 2027 2032 22C3 24-Hour Data 28.7% 3 serotype 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one 30% 35 36% 48-month 4D Molecular Therapeutics ' 5,6-methylenedioxy-2-aminoindane 50–59 52-week results 55% 5B 5alpha)-isomer 6-minute walk distance 7.5 mg 72% 7290 8(a 8.875% 80% 83% 88% 92% 95% A Life Covered A&B/SARS-CoV-2 AA Signature AAAAI AACR-NCI-EORTC AAD AAER AAIC AAPS NBC 2026 AARD gene AARP AATD-LD AAV antibodies AAV gene therapy AAV vector AAV-AIPL4 AAV-based gene therapy AAVB-081 AAVantgarde AAVrh74 AAVrh74 vector AB-1005 AB-2100 AB001 ABCA4 gene ABCL635 ABI-4334 ABO2203 ABP ABP-102 ABPI ABS-0871 ABS-1230 ABTECT ABTECT-1 ABTECT-2 ABX464 ACA ACCENT trial ACCESS II ACCESS model ACHIEVE-1 ACI-7104.056 ACP-101 ACP-204 ACR-2316 ACR50 ACT-01 ACT-02 ACTH receptor antagonist ACUA AChR-Ab ADA25 ADAM11 protein, human ADAMTS-5 ADAPT-PD study ADEL ADEPT ADEPT-2 trial ADMET ADNI4 ADPD ADSs ADVC001 ADVOCATE program ADVOCATE trial ADX-626 AFFINITY DUCHENNE trial AFFIRM-1 AFFIRM-1 phase 3 trial AFPs AGC AGCM Biogen investigation Stratify test AGIO AGXT gene AHA AHB-137 AHB-171 AI Assist AI Factories AI Proteins AI Stethoscope AI antibiotic discovery AI automation AI biomarker AI biopharma AI cardiology AI clinical trials AI collaboration AI doctor AI foundation model AI guardrails AI health app AI health technology AI healthtech IPOs AI humanoid robots AI imaging AI innovation AI lab AI lung cancer AI molecular design AI molecule models AI oncology imaging AI refills AI regulation AI scientist AI solutions AI supercomputer AI teammates AI therapeutics AI token AI tools AI ultrasound AI workflows AI-Based Protein Design AI-ECG AI-Powered Test AI-assisted drug discovery AI-based AI-based drug discovery AI-designed drugs AI-designed molecules AI-designed pill AI-designed viruses AI-discovered drugs AI-driven antibody AI-engineered antibody AI-generated AI-guided AI-guided design AI-native biotech AI-native health system AI-native regulatory automation AI-powered credentialing AI-powered diagnostics AI-powered drug discovery AI-powered healthcare AI-powered solutions AI-ready AI/ML-enabled product AIDS Healthcare Foundation AIM-MASH AIR-001 AJ1 AK006 AK0406 AK138D1 AKAP9 protein AKAP9 protein, human AKT Inhibitor AKT inhibitors AKY-1189 AL ALE1 ALK-001 ALK7 ALKOVE-1 trial ALKS ALLR ALNY ALOFT trial ALPHA3 ALPHA3 trial ALT-B4 ALT-positive ALTO-101 ALTO-203 ALX ALX2004 ALZ-801 AMA AMED AMGN AMKD AMONDYS AMP KRAS Vaccine ELI-002 AMPA receptor modulator AMPA-PAM AMPLIFY AMPLIFY-7P trial AMT-191 AMWC AMX0035 AN2 ANDA ANNE ANX005 AP3 APG-5918 APIs APJ APLAS APOE program AQUILA study AR navigation ARC-EX System ARCB Investment ARCT-032 ARD-201 ARG-007 ARIA ARIA risk ARIA-E ARID1A mutation ARO-ALK7 ARO-APOC3 ARO-C3 ARO-INHBE ARO-PNPLA3 ARO-SNCA ARPA-H ADVOCATE ARPA-H THRIVE ARPA-H grant ARROS-1 ARROS-1 trial ARTBIO ARTV ARV-6723 ASAH1 gene ASC41 ASCEND trial ASCENT ASCO GI 2026 ASCO preview ASCO-GU ASCO25 ASMB ASPIRO trial ASPR ASRS ASTRALS ASTX029 ATG-022 ATG-125 ATG-207 ATHENA ATI ATLAS-UC ATMP regulation China ATN ATNM-400 ATR ATR/mTOR Inhibitors ATSN-101 ATSN-201 ATTAIN-2 ATTO-2306 ATX01 AURKA inhibitor AURN001 AVB-114 AVD-104 AVP-786 AVTX AVZO AXS-14 AZD0120 AZD0780 AZD4241 AZD5004 AZD5462 AZSTARYS AZUR-1 AZURE-1 AbCellera stock AbForge ® platform Abata AbbVie CEO AbbVie New Jersey AbbVie Robert Michael Abbas Kazimi Abbisko Cayman Abbisko Therapeutics Abbreviated New Drug Application Abcam Abdominal Fat Abdominoplasty (procedure) Abe Bassan Abecma AbelZeta Abeona 's Abetalipoproteinemia Abivax falls Abivax stock Abogen Biosciences Absci Academia (organization) Academy of Pediatrics Acadia Pharmaceuticals Accelerate Diagnostics Accelerate Growth " programme Accord BioPharma Accrual Accuray Acet Achieve Life Sciences Acne Vulgaris Acoramidis Acquired Immunodeficiency Syndrome Acrivon Acrobat Genomics Act of Documentation Actemra Actimab-A Actin-Binding Protein Acting Actinium Pharmaceuticals Actio Actio Biosciences Actithera Active Activin E :* * Actuate AcuCort Acute leukemia Adagene Adaptive Biotechnologies Adaptyv Bio Adcetris Adcomm Adcoris Addictive Behavior Adenomatous Polyposis Coli Adenosine deaminase deficiency Adenovirus Infections Adherence (attribute) Adherence To Medication Regime Adicet Bio Adipose tissue Aditum Adjunctive Orthodontic Procedure Adjuvant Melanoma Admilparant Adolescence AdvaMed Diabetes Sector Advair Advanced Imaging Suite Advanced Labs Advanced Manufacturing Technology Advanced Renal Cell Carcinoma Advanced Therapy Medicinal Products Advanced Urothelial Carcinoma Adverse reaction to drug Advisory Board Advita Ortho Aerska Aethlon Medical Afami-cel Africa Afya Limited Agenesis of corpus callosum Agentic Harmonization Assistant Agentic Test Agenus Aggressive Aggressive Periodontitis Agilent Agitation Ahmed ElNawawi AiTEM AilsynBio AimedBio Ainnocence Airna Aizen Therapeutics Ajax Health Ajax Therapeutics Ajay Nirula Ajovy Akeega Akeso 's Akido Al-powered Alamar Biosciences Alan Ashworth Alan Bash Alan Sandler Alarm device Alberto Lopez Toledo Albireo Portfolio Albuminuria Alchemab Alcohol dependence scale Alcohol or Other Drugs use Aldose Reductase Inhibitor Alejandro Weinstein Alembic Pharmaceuticals Alesta Therapeutics Alexei Algen Biotechnologies AlgoTx Allakos Allarity Allarity Acquisition Corp. Allergan Allergy Specialty Allergy to peanuts Allison Candido Allogeneic Anti-CD19 1XX-CAR T-cells FT819 Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880 Allogeneic bone graft Alloimmune thrombocytopenia Allumia Ventures Alluminox Alma AlphaDirect technology AlphaFold AlphaLab AlphaMedix Alphabet Alphamab Oncology Altanine Altasciences Alternative Funding Programs Altman Alto Neurosciences Altuviiio Alumni Alva Therapeutics Alvelestat Alveltamig Alyftrek AlzeCure Alzey investment cut Alzheimer 's agitation Alzheimer 's disease psychosis Alzheimer 's treatment Alzheimer's Disease AmBisome Amar Thyagarajan Amarin Amarin Pharma Amazon Bedrock Amazon Health Amazon Pharmacy Amazon Web Services Amazon Web Services of Ambient AmbioPharm Ambrosia Ambrosia Biosciences Ambrx American Cancer Society American College of Cardiology American Depositary Receipts American Epilepsy Society 2025 American Lung Association AmericasMedicines.com Amethyst Amezosvatein Amgen Tepezza active Amgen Uplizna Amgen obesity pipeline Amit Singal Ammonia level finding Amneal Amolyt Amondys Ampere Amphastar Amplify trial Amplitude Amplitude Therapeutics Amsterdam facility Amtagvi Amylin Candidate Amyloid-targeting therapy AnTenGager Anabolism Analog Analysis of substances Anaphylm Anatol Andembry Andreas Goutopoulos Andreas Wallnöfer Andreessen Horowitz Andrew Grethlein Andrew O Andrew Witty Androgen-Insensitivity Syndrome Andy Thomas Anesthesia procedures Ang2 Angela Breton Angelini Industries Angiotensinogen Angle Health Anima Biotech Animal Health Animal Testing Animal Welfare Animal mane Anixa Ankylosing spondylitis Ankyra Therapeutics Ann Arbor Anne Anne Wojcicki Annexon Anniko Annual Reports Anomaly Ventures Anovo Ansa Ansa Biotechnologies Anselamimab Anson Industrial Park Ant Afu Ant Group Antares Antares Therapeutics Anterior Anthos Anthropic Anthology Fund Anthropological Culture Anti-BTN3A Agonistic Monoclonal Antibody ICT01 Anti-CD19 Monoclonal Antibody Anti-CD36 mAb Anti-CD47 Monoclonal Antibody AK117 Anti-CD52 Monoclonal Antibody ALLO-647 Anti-Claudin18.2 ADC CMG901 Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 Anti-Kickback Statute ( Antiandrogen therapy Antibiotic Resistance Antibiotic Resistance, Microbial Antibiotic therapy Antibody Solutions Antibody Therapeutics Antidepressive Agents Antineutrophil Cytoplasmic Antibodies Antitrust Probe Anumana Anxiety Anything Anzupgo Apheris ADMET Network Apis (invertebrate) Apnea Apollo robot Appeals court decision Apple App Store Apple Health Applied Pharma Apptronik Apretude Apriori Bio Aquestive Therapeutics Aquipta Aqvesme Araris Arbitrating Arbuckle Arc Bio Arch Biopartners Arch of foot Archimed Architecture Arcturus Arcturus Therapeutics Arcturus Therapeutics ' Arecaceae Arena BioWorks Areteia Arexvy Arginine Vasopressin-Neurophysin II Preproprotein Argo Biopharma Arikayce ArkBio Arpeggio Biosciences Arrowhead RNAi Arrowhead plozasiran Arsenal Biosciences Artera Arteriosclerosis Arthritis Artificial (qualifier value) Artificial cardiac pacemaker Artis BioSolutions Artiva Biotherapeutics Asarina Ascenta Capital Ascentage Pharma Ascidian Therapeutics Ashiq Khan Asia assets Asia-Pacific Asian Americans Asian Indian AskBio Aspect - Kind of quantity Aspen, Bach Flower Essence Assertio Assertio Holdings Assured Astellas Pharma Astex Astra Peptides AstraZeneca 's AstraZeneca Truqap Faslodex Astria Astrin Biosciences AstroRx ® Atai Life Sciences Atara 's Atara Biotherapeutics Atavistik Bio Ataxia Telangiectasia Ataxia, Spinocerebellar Atea Atherosclerosis Athetoid cerebral palsy Athlone facility Atirmociclib Atman Health Atropos Health Atsena Attack device Attention Attenuated by (contextual qualifier) Attruby revenue growth Atumelnant Atypical Aubagio Aubrey C. Galloway Audit Committee Chair Augmented Reality August 12 August 2028 August 2029 August 3 Aurion Biotech AusperBio Authority Autism Spectrum Quotient Autism trial Autofluorescence Autoimmune Alliance Autoimmune Chronic Hepatitis Autoimmune Therapies Autoimmune inflammation of skeletal muscle Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F Autologous CD19 CAR-expressing T-cells YTB323 Autolysosome Automate (invertebrate) Automated (qualifier value) Automated Cell Therapy Autonomous Healthcare Autonomous Research Auvelity Avacta Avadel Avadel acquisition Avalo Therapeutics Avantect Avantect ® Pancreatic Cancer Test Avastin Avenzo Avenzo Therapeutics Average Avicanna Avobis Bio Avoro Axelios sequencer Axial Axiom Biosciences Axoltis Axplora Axsome Axsome Therapeutics' Ayble Health Ayvakit Azure A³ Strategy B Cell Llama B cell immunomodulator program B-cell Select ™ technology B-cell diseases B-cell malignancies B7-H3-targeted sialidase B7H3/PTK7 bispecific TOP1 BAFF/APRIL BAFF/APRIL inhibitor BAFF‑R BAG3-associated BATNA BBB BBB shuttle BBI-355 BBI-825 BBOT BBP-418 BCB-276 BCCNS BCG Vaccine BCG-unresponsive BCL-2 Inhibitor [EPC] BCL11A gene BCL6 gene BCMAxCD19 BCR BCVA BDM BDTX-4933 BEAM-302 BEHOLD-1 BEXLUTRY BEXMAB BHB-1893 BI BIC/LEN BINSA BIO board BL-B01D1 - 303 BLSM BLVD-101 BMB-101 BMB-105 BMRN BMS-986177 BMS-986322 BMS-986353 BMS-986497 BMS-Hengrui BNT211 BPI gene BPL BRBM BRCA BRCA2 gene BRENTUXIMAB BRIO I BRIO II BROADWAY BROADWAY trial BRUNELLO BRUNELLO trial BT-267 BT-409 BTK degrader BTKi BTN3A BW-20829 BX211 BXCL501 BXLS VI BYD Baby KJ Bacillus cereus Bacterial Endocarditis Bacterial Infections Bacteriophages Baebies Baker Balance Sheet Balinese language Bambusa Therapeutics Bangalore plant Barakat syndrome Barbara Barinthus Barrow Neurological Institute Basal Cell Nevus Syndrome Basketball game Basking Ridge Basque Country Bausch Health Baxter International Bayley-4 Beacon Beacon Therapeutics Beat Becker Hewes Beeline Beeline Medicines Beginning Behcet Syndrome Belite Bio Belén Belén Garijo Ben Cline Bench International Benedikt von Braunmuehl Benlysta Bepranemab Beqalzi Beqvez BerGenBio merger Berkeley Berkeley Vincent BetterHelp Bettis Bezos Expeditions Bharat BiLockCatcher Bial Bias (Epidemiology) Bicara Therapeutics Bicillin L-A Bicycle Bicycle Health Bicycle Therapeutics Big Data Big Pharma investors Big Picture Bio Bilbao Biliary Atresia Bilirubin Bill Adams Billerica Billion Collaboration Billioux Binding action Bintrafusp alfa Bio + Health Bio-Hermes Bio-Informatics Bio-Rad Laboratories Bio-Thera Bio100 BioAtla BioCity BioClec BioCryst BioCytics BioGPU BioImpact BioInnovation Institute BioLife Solutions BioPorto BioStem BioVU BioVie Biochemistry Biocodex Biocon Biologics Bioconjugation Platform Biocytogen Biodexa Bioeconomy Bioepis Biogen CEO Biogen Tysabri Sandoz Biohaven troriluzole Bioliberty Biologic Preservation Biological Response Modifier Therapy BiomX Biomanufacturing Strategy Biomedicine Biomolecular AI Bionyra Pharma Biopharm Biopharma AI CRM Biopharma regulatory issues Biopharma trade war Biopharmaceuticals Biosecurity Bioshield Biosimilar Drugs Biotech Competition Biotech Fundraising Biotech Layoff Tracker Biotech Market Biotech pipeline shift Biotechnology Advantage Biotechnology Investment Biotechnology perspective article Bipartisan Senate bill Bipartisan Support Bipolar I disorder BirchBioMed Bitopertin Bivamelagon Bixlenvo Bizengri Blackwell Ultra GPU Bladder Risk Blastic plasmacytoid dendritic cell neoplasm Blepharitis Blighia sapida Blinded Blood Blood Pressure Insights Blood Transfusion Blood coagulation tests BlossomHill Therapeutics IPO Blue Owl Healthcare Blueprint Medicines Board Directors Board Resignation Board change Boards (medical device) Bobby Hunter Body Composition Body fluid retention Boehringer Ingelheim Germany Boltz-1 Boltz-2 Bone Density BoomRay Pharmaceuticals Boost Boston Children 's Hospital Boston Pharmaceuticals Boston event Boulevard Bio Boundless Bradley Campbell Brain Brain Implants Brain Injuries Brain Research Brain hemorrhage Brain stimulation Brain-Penetrant Drug BrainChild Bio BrainSpace BrainTransporter platform BrainTransporter technology Brainomix 360 Brainshuttle Breakthrough Device Designation Breast Acoustic CT Brendan Doran Brenig Therapeutics Brexit impact Breyanzi Breye Therapeutics ' Breztri Brian Armstrong Brian Cherry Brian McKelligon Brian Thomas BridGene BridgeBio Pharma Q2 2026 revenue beat BridgeBio Pharmaceuticals Briggs Morrison Bright Minds Biosciences Brilaroxazine Brilliance Studies Bristol-Myers Squibb British Neuro-Oncology Society BroADen Phase 1b trial Bruce D. Forrest Bruin-CLL-314 Bruker Corporation Bruton's Tyrosine Kinase Inhibitors [MoA] Bullous pemphigoid Bureau of Industry and Burst suppression BurstDR Business Update Call Bylvay Bysanti C-CAR031 C-reactive protein C-suite C-suite changes C1QA gene C3 G C3 complement inhibitor C3 glomerulopathy C4 Therapeutics C5 inhibitor CAB CABA-201 CABIN1 protein, human CADENCE study CADe/CADx CADx CAH CALM-1 CALM-2 CALR gene CAMBRIA-1 CAMBRIA-2 CAMP4 CAMPSIITE CAN10 CAP-002 CAPItello-280 CAPS-5 CAR T-cell CAR-T clinical trial CAR-T engineering CAR-iNKT cells CARDINAL study CARDIO-TTRansform CARDIO-TTRansform trial CARIS Life Sciences CARTITUDE-1 CARTITUDE-2 CARsgen Therapeutics CB1 inhibitor CBB-120 CBC Group CBER CDER orphan drugs CBI-1214 CBX-250 CBX-663 CD CD19/CD20 CD20 Antigens CD20-directed therapy CD3 T cell CD33 antigen CD38 Antigen CD38 monoclonal antibody CD38-directed antibody CD4 + T-cell CD4 + T-cells CD47 Antigen CD8 T cells CDASI-A CDC vaccine recommendation CDC7 protein, human CDH17 protein, human CDH6 gene CDK inhibitors CDK2/4 degrader CDK4 inhibitor CDMO platform CDMO/CRO CDOO CDR-SB CDTO CE-IVD CEDAR study CELC CELESTIMO CELIA Phase 2 trial CEO Kai Beckmann CEO Luke CEO Mike CEO Mike Doustdar CEO Thomas Schinecker CEO Ulf Hannelius CEO Vas Narasimhan CEO appointments CEO replacement CEO resignation CEPI CETP CF CFD-FOLR1 CFIUS CGRP inhibitor CHAPTER-3 CHARM Therapeutics CHEK1 protein, human CHORD trial CHRS CHW Access Act CIAS CIDP CAPTIVATE trial CIHR CIRM CITY-FXI CITY-RBP4 CJR-X Model CLD-423 CLDX CLIA CLIA-waiver CLIC4 gene CLL-314 CLL/SLL CLN-081 CLUS CMC CMO appointment CMS Interoperability Framework CMT-SORD CNS activity CNS drug development CNS pipeline CNS-3D CNS-focused merger CNS-penetrant COGS COINS Act COM503 COM701 COMP005 COMP006 COMPOSE trial COO COPD-OMA CORALreef Lipids CORALreef trial CORALreef trials CORDStrom CPI-refractory tumors CPO CR-001 CRB-701 CRBN gene CRC test CRISPR CRISPR gene editing CRISPR therapies CRISPR therapy CRM chromium picolinate CROSSJECT CROs CSB-001 CSL-Behring CSNK1E gene CSP2026 CT analysis CT-132 CT-155 CT-388 CT-868 CT-P72 CTAD CTMS CTMX CTPS1 inhibitor CUE-501 CV features CVRM CX-2051 CXCR4 gene CYPRESS study Cabaletta Cabaletta Bio Cabometyx Cadonilimab CagriSema Wegovy Calcified (qualifier) Calico Califf California residents Calley Means Calypso study Cambridge Massachusetts Cambridge R&D headquarters Cambridge research labs Camilla Harder Hartvig Camilla Sylvest Camurus Canadian Canadian Cancer Society Canal Row Advisors Cancer Diagnosis Cancer Drug Sales Cancer Drugs Fund Cancer Prevention Cancer Research Institute Cancer Risk Cancer Survival Candel Candid Therapeutics Cannes Cantargia Cantor CapVest Partners Capability Capital Expenditures Capital Markets Capitol Hill Caponago Caps Capsida Biotherapeutics Captain T Cell Carbapenems CarbonAI Carcinoma in Situ CardIQ Cardiac Arrhythmia Cardiac ablation Cardiac care Cardiac monitoring Cardiff University CardioMEMS Hero Cardiospermum grandiflorum Cardiothoracic surgery specialty Carduelis cannabina Caremark Caremark Rx Caris Detect Caris MI Carl Dugart Carl June Carlo Incerti Carlos Quezada-Ruiz Carole Ho Caroline Dorsa Carterra Cartography Caspian Therapeutics Catabolism CatalYm Catalio Capital Management Catalys Pacific Catalyst Pharmaceuticals Catherine Bovenizer Causaly Cecile Guegan interim Cell Shuttle platform Cell Transplantation Cell-Free DNA Cell-free protein CellDx-Tissue CellOPTIQ Cellular Origins Cellular Reprogramming Cellular Tissue Celtic Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Centers for Medicare and Medicaid Services Centessa Centiloid Centiloid scoring Central Nervous System Agents Ceperognastat Cerberus Ventures Cerebral Adrenoleukodystrophy Cerebrotendinous Cereno Scientific Ceribell Cevidoplenib Chad Chagas Disease Challenge:Type:Point in time:^Patient:Nominal Chance Act Changchun GeneScience Pharmaceutical Change Management Charcot-Marie-Tooth Disease Charles Fuchs Charles Ryan Charles Weissmann ChatGPT Health Chaudhuri Chechen language Checkpoint Therapeutics Chemical Science Chemify Chemistry42 Chemoradiotherapy Chemputation Cheryl Blanchard Cheryl Lubbert Chickenpox Vaccine Chief AI Officer Chief Clinical Officer Chief Development Officer Chief Digital Chief Health Officer Chief Marketing Officer Chief Quality Officer Chief Revenue Officer Chief Science Officer Chief Scientific Officer Chief Strategy Officer Chiesi Global Rare Diseases Chiesi Group Children Program Chimagen Biosciences Chimera organism Chimerix Chimerix acquisition China 's China approval China legal issues resolution China pharma China trial China-Derived Drug China-sourced asset Chinese Neurosurgical Journal Chinese study Cholesterol Drug Cholinergic Receptors Chondrosarcoma Chordoma Chorea Chris Barry Chris Lance Chris Shibutani Christiane Bardroff Christopher Martin Christopher Viehbacher Chromatography Chromosome 7 Short Arm Chronic Care Management Chronic Condition Chronic Inducible Urticaria Chronic Inflammatory Demyelinating Chronic granulomatous disease Chronic heart failure Chronic lung disease Chronic refractory cough Cicatrization Cigna Cigna 's Ciliary Neurotrophic Factor CinCor Pharma Cingulate Cipla CirCLIQ Circuit Cirrus Citation City Therapeutics Civil Rights Act Clarametyx Biosciences Claris Biotherapeutics Clarius handheld ultrasound Claros facility Class Class 1 resubmission Class A Class II Medical Device Classical galactosemia Claude Allary Claude Science Claudin 18.2 ADC Claudin-5 Claudins ClearStrand-ASD Clearmind Medicine Clesrovimab CliCr Click Therapeutics ClinVar CliniQuantum Clinic Clinical Complete Response Clinical Deployment Clinical Equipoise Clinical Evaluations Clinical Evidence Clinical Investigations Clinical Investigators Clinical Relevance Clinical Response Clinical Setback Clinical Trial Suspension Clinical Trial Termination Clinical pharmacology discipline Clinical stage finding ClinicalTrials.gov CloakLink linker technology Cloning Vectors Closed Loop Medicine Clyde Biosciences Clywedog Therapeutics Co-Diagnostics Co-Dx PCR platform Coartem Cochrane review Codon, Nonsense Coefficient Bio Cognition Therapeutics Cognitive Cognitive Function Neuroimaging Cognitive function: initiation Cognitive function: planning Coherus Oncology Cohort Coinbase Coleman Colin Murdoch Collegium Collegium Pharmaceutical Colonic Polyps Comac Combinations (Undergarment) Combined immunodeficiency disease Comirnaty Commerce Commerce Department Commercial Officer Committee Community Clinical Oncology Program Community Health Workers Comorbidity Comparative Genomics Compass Compassionate Use Compensation Committee Complement Factor B Complement Membrane Attack Complex Complex Compliance behavior Compound MOA Compugen Computational Biology Computer software Concentra Concern Concurrent Condition Congenital Cytomegalovirus Infection Congenital adrenal hyperplasia Congenital deafness Congenital disorder of glycosylation type 1A Congenital emphysema Congress reauthorization Congressional Hearings Connect (action) Connecticut biotech Connectivity Consent Forms Consideration Constellation platform Constitutional Challenges Consumer Consumer Behavior Consumer Rx Continuance of life Continuous Delivery Contraceptive Implant Contraceptive methods Contract Pharmacy Law Contrave Control Plans Controlled release Convenient Copenhagen CorMedix Corbus Pharmaceuticals Corcept Therapeutics' Core CorestemChemon Corneal epithelial defect Cornerstone Robotics Cornucopian Capital Corporate Update Corrective Correspondence as Topic Corsera Health Corstasis Cortechs.ai Corvus Corvus Pharmaceuticals Corxel Pharmaceuticals Cosette Pharmaceuticals Cost Base Cost Base Program Cost Control Cost Plus Drugs Cost savings programs Counsel Health Country of Wales Court of Chancery Covalent Interaction Coya Therapeutics CpcPH Craig Crews Craig-Hallum Cranial Navigation platform Craniodiaphyseal dysplasia Craving for alcohol Create Medicines Creatine Kinase Credentialing Credit - Transaction Type Crescent Biopharma Creyon Criminal Justice Crisis Cristal Therapeutics CrossBridge Bio Crossbow Therapeutics Crown Bioscience CryoStor Cryopreserved Cells Cryptigen CryptoMap platform Ctexli Cu-Zn Superoxide Dismutase Cues Curapath Cure (remedy) CureVac acquisition Curevo Vaccine Curium Pharma Curon Biopharmaceutical Curve Biosciences Cushing 's syndrome Cutaneous sarcoidosis Cybersecurity Breach Cyclerion Therapeutics Cyclic GMP Cyclic Peptides Cyclin-Dependent Kinases Cynata Cyprium Therapeutics Cyprumed Cystic Fibrosis Foundation Cystic fibrosis sweat test Cytek Biosciences Cytokine Release Syndrome Cytology diagnosis Cytomegalovirus Infections DARPA-funded initiative * * DAWN DAYBU DAZALS trial DCT gene DDAF DDX11-AS1 gene DECODE DESTINY-CRC02 DESTINY-Lung01 DESTINY-PanTumor02 DFO DFTX DGX DIA AI Consortium DIAGNODE-3 DIPG DLBCL-1 DLL3 DLL3-targeting therapy DMC DMD cardiomyopathy DMR-001 DMX-652 DNA Repair DNA Sequence DNA Sequence Rearrangement DNA replication inhibitors DNA synthesis screening DNA-damage response DNA-encoded library DNDi DNL593 DNTH DNTH212 DOGE 's DORIS remission DPHARM DREAMM DREAMM-8 DSC3 gene DSO DT-101 DT-216P2 DT-9081 DT120 DTC Campaign DTX301 DTX401 DURECT DURGA-1 DXCM DYN DYNAMIKA DYNE-251 DaX AI platform Daiichi oncology Damon Lanphear Dana-Farber Danish pharma Danyelza Dark Blue Therapeutics Dark color Darpa DartsBio Darwazah Dash Bio Dasynoc Data Analytics Data Fidelity Data Lakes Data Management Data Release Data Science Data Security Data-Driven AI Databricks Datar Cancer Genetics Dato-DXd Datroway breast cancer Dave Denton David Guyer David Liu David McGuire David Meek David Schenkein Day 2 Daymark Health DeLLphi-305 DePuy Synthes Deal Flow Deal Structure Decanoates Decatur Illinois December 2025 Deciparticle nanomedicine platform Deciphera acquisition Decnupaz Decompression Sickness Decreased Deep Brain Stimulation Deep Learning Deep Science Ventures Deep Vein Thrombosis DeepMind DeepSearch DeepSeq DeepView System Deerfield Deglutition Disorders Degrader-Antibody Conjugates Degree or extent Degrons Del-zota Delta Sleep-Inducing Peptide Delusions Dementia Research Institute Demis Democrats Dendritic Cell-Autologous Lung Tumor Vaccine Denifanstat Dennis Dean Dental Solutions Denton Department of Justice Department of War Departure - action Depemokimab Deraphan Dermatographic urticaria Dermis Derrick C. Li ; Chief Business Officer Descovy Desiccation Design Desire for food Desiree Cain Deutsche Bank Develop Developing Developmental (qualifier value) DeviceGuide Dexcom G7 Dexpramipexole Diabetic Nephropathy Diabetic monitoring - injection sites Diagnostic Accuracy Diamond Therapeutics Diamyd Medical Diastasis Diet, High-Protein Dieta Health Difficult-to-Express Proteins Diffuse Glioma Diffuse Intrinsic Pontine Glioma Digital Technology Digital Trial Digital X-ray Digital digestive health Digital innovation Digital therapeutics Digital tool Dimerix Dimitri Azar Diorasis Diphosphonates Direct-to-Consumer Advertising Direct-to-Patient Programs Directed share Disability Disasters Disclosure Discoid lupus erythematosus Discussion (procedure) Disease Evidence Principles Diskus Dispatch Bio Disputes Distribution District of Dizal Dizal Pharmaceutical Doctronic Doctronic AI system Dong-E-E-Jiao Donna Haire DopApp Dopamine D2 Receptor Dorsal Dose-Limiting Doustdar DoveTree Medicines Dr. Gavin Dawe Dr. Marnix Bosch Dr. Sara Brenner Draig Dreamforce Dren Bio Dresden Drexel University Drug Compounding Drug Development Tool Drug Evaluation, Preclinical Drug Kinetics Drug Negotiation Program Drug Overdose Drug Recalls Drug Repositioning Drug development costs Drug licensing Drug packaging industry Drug resistance Dry AMD Dual-chamber systems DualScreen Dualitas Therapeutics Duato Duet, Prenatal Multivitamins Duke Health Dukoral Dupixent-in-a-pill Durability Data Duravyu Duvakitug Dyggve-Melchior-Clausen syndrome Dynamic Shared Ownership Dynavax Dyno Therapeutics E-688 E-Scopics E. coli disease E100 survey E2814 E6(R3 EB613 EBV-positive PTLD ECG analysis ECG-AI ECLIPSE program ECT EDEN EDIT-401 EDIT-401 program EFS gene EHA Congress EHR EKF Diagnostics ELA026 ELA822 ELEVATE-44 ELP Technology ELPIS II ELSC ELT ELV001 ELVN EMA Approval EMA China EMBARK EMBARQ-CSU1 EMBARQ-CSU2 EMBER-3 EMBER-3 trial EMERALD-3 EMPEROR EMPEROR Phase III trial ENCELTO ENERGY study ENT1 ENV-101 ENV-308 ENV-6946 ENaBL Platform EO-1022 EO-3021 EOC EOS-215 EOS-984 EP'949 EP4 Antagonist ONO-4578 EP4 antagonist EP4 receptor antagonist EPCAM gene EPCORE EPKINLY EPRAD ER+/HER2- ER-100 ER-Positive HER2-Negative Breast Cancer ERAS-0015 ESC25 ESGO ESK-001 ESMO IO ESO-T01 ESSDAI ESSENCE trial ESTERASE C ETA ETX301 EU AI Act EU AI Act health EUA EVO301 EVOKE trial EVOKE-03 trial EVOQ EXCALIBER-RRMM EXHALE-4 EY EYPT Early Intervention (Education) Early-Stage Pipeline East Asian American East Asian Americans East Hanover 2026 East Windsor facility Ebglyss Eclampsia Ecnoglutide Economic Conditions Economic Growth Economic Investment Committee Edap Edenbridge Edge AI Edison Oncology Edison Scientific Editas Medicine Editors Corner Edotreotide Education, Medical Edward Conner Efluelda Efruxifermin Eftilagimod alfa Eight Ekterly Elasticity Imaging Techniques Elecsys pTau217 Election Proposal Electrocardiogram Electrocardiography, 12-Lead Electrocardiography, Ambulatory Electroconvulsive Therapy Electronic Electronic Health Records Eledon Elektrofi ElevAAte Elevar Elevar Therapeutics Elevara Medicines Eli Lilly & Co. Eli Lilly ; Novo Nordisk Eli Lilly David Ricks Eli Lilly Ventures Eli Lilly Zepbound Eli Lilly acquisition Eli Lilly competition Eligible Elinzanetant Elix Elizabeth Montgomery Elkridge facility Ella Platform Eloralintide Elrexfio Elsa Emblaveo Emerge trial Emergency Department utilization Emergency Situation Emergency Use Authorization Emergency department patient visit Emi-Le Emideltide Emirati Genome Program Empower Pharmacy Empowered Empress Emrelis Enanta Enbrel Enbumyst Encapsulated (qualifier value) Encephalitis Encephalopathies Encryption End Point Endeavor Endevica Bio Endocrine System Diseases Endogenous Eneboparatide Energy Score Engineer Engineering Enh3ance trial Enki generative AI Enlaza Enrollment Entera Bio Enterome Enterprise Entity Entrada Therapeutics ' Entyvio Enveda Biosciences Environmental pool Envy Enzeevu Enzyme Replacement Therapy Enzyme Therapy EpiVax Epicrispr Biotechnologies Epidemic Epidemic Preparedness Innovations Epigenetic Silencing Epigenic Epiminder Epitopea Equillium Equipment Equipment and supply inventories Erbitux Erelzi Eric Cantor Eric Dube Erica Palsis Erica Taylor Erik Atkisson Erika Porcelli Erleada Erleada apalutamide Erleada upstream data ASCO Erythropoietic Protoporphyria Escalation Eshkenazi EsoBiotec Esophageal Neoplasms Essential Tremor Ester Banque Estimated Estrogen receptor positive Ethics Ethics Committees Ethyreal Bio Etiome Eua (gastropod) Eucalyptus Eukaryotic Cells Europe market European Commission approval European Group for Blood and Marrow Transplantation risk score (assessment scale) European Hematology Association European Respiratory Society European Respiratory Society Congress European Union Evaluate report Evan Rachlin Everest Everest Medicines Everlywell Evfraxy Evidity Health Capital Evo1 Evo2 Evoked Potentials Evolvus Evopoint Biosciences Evorpacept Evrysdi Ewings sarcoma Ex-FDA ExPEC9V Exact brand biomedical or dental material Excalipoint Therapeutics Excellergy Exciva Executive Board Executive Board Changes Executive Leadership Team Executive Order 14273 Executive Team Change Executive Vice President Exfoliation Syndrome Exit activity Exl-111 Exon Skipping Exons Exophthalmos Expanding Expedited IND Expedited IND Pilot Program Expedition Medicines Expedition Therapeutics Experience Experience Suite Expert Systems Expiration Exposome Extencilline External Director External Ventricular Drain Extra-osseous Ewing's sarcoma Eye safety EyeBio EyePoint Pharmaceuticals Eyebrow structure Eyelash Eylea biosimilar FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 FAERS FAK/ALK/ROS1 Inhibitor APG-2449 FALKON FB102 FDA-approved therapies FDA-cleared AI FDA/EMA regulatory pathways FDR FEINGOLD SYNDROME 2 FGFR1 gene FGFR3 inhibitor FGFR3 protein, human FGFR3-altered FHD-909 FHIR FIGHT China Act FILSPARI FINDER FINE-ONE trial FINEARTS-HF FL-501 FOG-001 FORTE FORTIFY FORTITUDE-101 FORTITUDE-102 FREEDOM2 FSHR-targeted CAR-T/CER-T FSP FT839 FTC FTSE FUJIFILM Biotechnologies FUROSCIX FUS-ALS FXR314 FXS6837 FY 2027 FY2026 Facilities Association Facioscapulohumeral Factor XI antibody Factory Faeth Falls False Negative False Positive Family Fringillidae (organism) Family suidae Fanconi Anemia Farapulse Faro Faron Pharmaceuticals Fasenra Faslodex Favorable Favored Nation Fear (Mental Process) Febrile Convulsions February 1 Federal Appeals Court Federal reduction-in-force statute Federated AI Feeling content Fees Fellows Ferring Ferring Pharmaceuticals Fertility Fetal Hemoglobin Fetal and neonatal alloimmune thrombocytopenia Fetroja Fetus FibroBiologics FibroGen 's Fibroblast Growth Factor Receptor 2 Fibroblast Therapy Fibromatosis Fibrosis Fibrx Therapeutics Fidelity Management & Research Field Medical FiercePharma Fifth Circuit Fill/finish Finance Financial Stress Financial Times Findable Fine - adjective Firefly Bio Firelink platform First Half First-in-Human Clinical Trial First-in-Human Study FirstLight Fiscal 2026 Fitbit Air Fitness Centers Five-Year Plan Flare platform Flatiron Health Flexible Flow Flow Cytometry FlowMod Flu A/B Flu-028 FluBlok Fluad Fluad antitrust FluidCrystal technology FluoGuide Fluzone Focal glomerulosclerosis FogPharma Foghorn Therapeutics Food Allergy Food Policy Food, Processed For which was done Forced Vital Capacity Forma buyout Formal Dispute Resolution ( Format (qualifier value) Formation Bio Formula - diet Forrester Healthcare Forte Biosciences Fortrea FoundationOne CDx FoundationOne Genomic Profiling Founders Fund Foundry AI platform Fractyl Health Francis Francis Braun Francis Crick Institute Francis Wilson Frankfurt plant closure Free Mind ' Campaign Free Nurse Program ' FreeStyle Libre Freenome Test Frehemgo Fresenius Fresenius Kabi Freshworks Friedreich Ataxia Fujifilm Biotechnologies FulcrumSec Full-Life Functional improvement Fund I Fund III Furoscix ReadyFlow Fused structure Futility Analysis Future FutureTech II G12C inhibitors G12D inhibitor G3BP2 gene GABA A GABAergic interneurons GABPA gene GALA peptide GBS GC GCG GCG/GLP-1 agonist GDUFA IV GE8820 GEMINI trial GEN1107 GENGLYCOS GH Research GH001 GHO Capital GI care GI care program GI oncology GIPC1 gene GJB2 gene therapy GLA GLM101 GLOW2 GLP-1 medications GLP-1 medicines GLP-1 pipeline GLP-1 therapies GLP-1/GIP agonist GLP-1/GIP co-agonist GLP-1/GIP therapies GLP-1RA GLPG5101 GM-2505 GMMA platform GMP GMP violations GO29781 GPC3 protein, human GPCR pipeline GPCRs GPR182 gene GPT-5.2 GRADUAL-3 GRAS GRAS Reform GRT-001 GS-0321 GS-098 GS/pan-Notch Inhibitor AL101 GSBR-1290 GSDIa GSK 's GSK Emma Walmsley GSK Spero GT Medical Technologies GT801 GTPase-Activating Proteins GTX-102 GTx-104 GUB014295 GUBamy GUTC GXO GYM329 GZR18 Gabriel Baertschi GalNAc Galafold Galapagos layoffs Galatea Bio Galaxies Galaxy Brain Scientific Galderma Galecto Galera Therapeutics Galux Gambling Gamma/Delta T-Lymphocyte GammaTile Garda Therapeutics Gardasil sales Garetosmab Gas Chromatography Gastric Bypass Gastrointestinal Neoplasms Gastroparesis Gate Bioscience Gates Gates Foundation Gateway Labs Gaucher Disease Gavi Vaccine Gdańsk Gefion AI Supercomputer Gefurulimab GemPharmatech Gemini 3.1 Pro Gemini Enterprise GenAI GenEvolutioN GenSci GenSci148 GenScript GenScript Piscataway Pennington Gene Expression Profiling Gene Writing Gene-Edited Genelux Corporation Genentech Vice Presidents axed Genentech infectious disease General Data Protection Regulation Generalized pustular psoriasis Generations Generative Phosphoproteomics Generic Drug Makers Genes Genesis Molecular AI Genetic Biomarkers Genetic Kidney Diseases Genetic Leap Genetic screening method Genetic testing for cancer risk Genetix Biotherapeutics Genevant Genezen Geno J. Germano Genomenon Genomic Orientation Genotype Genus Aviceda Genus Malus Genus Marmota Genus Phalacrocorax (organism) Genus Unicorn Genus: Coronavirus GeoVax Geoff Hamilton ; Chief Financial Officer Geographic Intersection Geographic Locations German language Geron Geron Corporation Gestures Giant Cell Arteritis Giant Cell Tumors Gibson SOLA Gilde Gilead Merck HIV Gilgamesh Gitte Pugholm Aabo GlaxoSmithKline Glenmark Glenn Coleman Glial Fibrillary Acidic Protein Glickman Glioma Global Biobank Global Health Global Restructuring Global commercial operations Globalisation Globalization Glucagon-Like Peptide 2 GlucoGene trial Gluten GlycoEra Glycogen Storage Disease Glycomine Golden Triangle Good Machine Learning Practice Google Play Store Gordon Gossamer Bio Gossypium Gout GovEvents Government Shutdown Grabody-B Grace Niu Grade five rank Gram-negative infections GramEye Grand Prix Graphene Graves Disease Gray Delany Great Healthcare Plan Greater China Region Greenoaks Greg Verdine Gregory Verdine Grin Gross margin Groupe Bruxelles Lambert Growth Differentiation Factor 15 Growth Hormone Grünenthal Guardant Health Gubra Ventures Guggenheim Securities Guidance 2024 Guido Oelkers Guillain-Barre Syndrome Guillain-Barré syndrome Gumokimab Gurunathan Gut Stuff Gut-Brain Health GxP Gyminda Gyre stock H. Martin Seidel , H2H trial H5 avian influenza H5 bird flu HAELO HAM-A HB 2371 HCM HCP HCRTR2 gene HCTI HDAC2 wt Allele HDV HDV RNA HEMO HER2 companion diagnostics HER2- HER2-low HER2-low breast cancer HER2-positive metastatic breast cancer HER2-targeted therapy HER2-targeting antibody drug conjugate HER2-ultralow HER2CLIMB-05 HER3 HERCULES trial HFmrEF HH160 HHS Overhaul HHT HIF-2a HIV franchise HLFM HLX07 HLX43 HLX701 HM15912 HMPL-A830 HNGE HOOKIPA HOPE-2 trial HPP HPV-positive cancer HRCT HRR gene mutation HRS-9821 HS HS-001 HS-20093 HS-20094 HS-20110 HSCT HSE HSP90 Heat-Shock Proteins HSV-1 viral vector HT-SPR platforms HTGS26 HTS HU6 HUTCHMED Haduvio Hahn Hair Analysis Hairy Cell Leukemia Haleon demerger Halle Hallucinations Halo brace Halozyme Therapeutics Hamed Khalili Hamilton Anxiety Rating Scale Hamilton Anxiety Rating Scale ( HAM-A Hanmi Pharmaceuticals Hans Henrik Chrois Christensen Hansoh Hansoh Pharmaceutical Hansoh Pharmaceuticals Hantavirus Harbinger Harbour Mice technology Harbour Mice ® technology Harmony Biosciences Harout Harris Lazarre Harvard Research Harvard University Hassabis Hatteras Hatteras Opportunity Fund I Hatteras Venture Fund VII Haya HeFH Head of Growth Head of Non-Clinical Development Head of Strategy Headspace Health & Wellness Health Assistant Health Authority Questions Health Care Sector Health Care Systems Health Data Innovations Health Data Research Service Health Data Research UK Health Equity Health Guardian Health Improvement Health Information Systems Health Insurance Health Insurance Portability and Accountability Act Health Radar Health Services, National Health Workforce Health conditions:-:Point in time:^Patient:- Health education HealthCare Royalty Healthcare Payers Healthcare Triangle Healthcare products Healthcare services Healthy America Heart-2 Heather Clark Heather Knight Helen Jones Helicon Helicon peptides Helicore Helix (Snails) Hemab Therapeutics IPO Hematocrit procedure Hematological Disease Hemgenix Hemogenyx Hemoglobin Hemophagocytic Hemophilia B Henlius Biotech Hepatitis Hepatitis Delta Virus Hepatitis, Alcoholic Hepatoscope Hepcidin Mimetic PTG-300 Hepcludex Hereditary Diffuse Leukoencephalopathy with Spheroids Hereditary hemorrhagic telangiectasia Hereditary pancreatitis Hermanski-Pudlak Syndrome Hero Group Herpes NOS Herpes Simplex Infections Hers Herstellerabschlag Heterogeneity Hetronifly Hibsago Hickory trial Hidradenitis High Drop-Out Rate High dose High risk of High-Frequency Microsatellite Instability Hikal Hikma HilleVax Hillhouse Capital Hip Fractures Hippo Signaling Pathway Hiroyuki Sonoda HistoSonics exit Histone Locus Bodies Histone deacetylase inhibitor Histopathological aspects Hizentra Hoist device Holistic epilepsy management Home Testing Home Use Honeymoon Effect Hong Hongjiang Miao Hookipa Pharma Hopewell Horizon Therapeutics Hormone replacement therapy Hospital admission Hospital specialist Houman Ashrafian Hour House Appropriations Committee House Select Committee Houston Huahui Health Human Factors Human Glandular Kallikrein 2 Human Life Foundation Human Longevity Program Human Services Secretary Humanitarian Exemptions Humira patent expiration Hungary Huntington Disease Huyabio Hyaluronic Acid anchoring platform Hybrid AI Hybrid Care Model Hybridopa Hybrozyme Hypercon Hyperinsulinism Hypertrophic cardiomyopathy without obstruction Hypochondroplasia (disorder) Hypocupremia Hypoplastic Left Heart Syndrome Hypothalamic structure Hyrnuo Hytrulo Høiland I CAN trial I&I I&I startup IB6 IBC IBI363 IBTROZI ICANS ICER ICR Fort Lee ICU ICU bedside procedures ICU nursing shortages IDE034 IDEAYA IDEAYA Biosciences IDO1 IDS gene IDWeek IDeate-Lung01 IEC-HS IFNGS-high IGA IGC IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001 IGF-1R inhibitor IGF1R gene IGYNTE IHC IITs IL-13 antibody IL-17A monoclonal antibody IL-2 pathway IL-22 antibody IL-23 receptor antagonist IL-31 receptor alpha IL-6 inhibitor IL13 gene IL1RAP antibodies IL1RAP protein, human IL31 gene IL3RA protein, human IMC002 IMM2510/AXN-2510 IMNN-101 IMPACT trial IMVT IMforte trial IMvigor011 INAVO120 INBRAIN INBRX-101 IND-enabling studies INF904 INHBE INHBE gene INLIGHT INLIGHT trial INMB INNOVOTEX INOVIO INTI INZ-701 INmune Bio IO Biotech IO-based IPG IPS test IQLIK IRAK3 gene IRAK4 gene IRS ISAC ISB ISM-001 ISM4808 ISPPD ITK gene ITP ITZ101 IV-equivalent IVD testing Ia Iban language Icatide Icebergs Ichnos Glenmark Icovir Idar-Oberstein Identification (Psychology) Idvynso Ifosfamide/Methotrexate/Procarbazine protocol IgG4-RD IgG4-related disease IgM antibodies IkT-001Pro Ilant Health Illicit Drug Public Policy Illumina Ventures ImCheck Therapeutics Image Analysis Group Imagio Imaging System Imdylltra Imitation Imjudo Imlunestrant Immunai Immune Activation Immunic ImmunoForge ImmunoGen acquisition ImmunoPrecise Antibodies Immunoassay method Immunocompromised Host Immunofoco Immunoglobulin M Immunoglobulins Immunopharma Immunoprecipitation Immunosuppressive Agents Immutep Impacts, Environmental Implementation Improved Improving (qualifier value) Imsidolimab Imvax In Vitro [Publication Type] InMed Pharmaceuticals Inadequate (qualifier) Inato Incentives Inceptive Incheon Inclusion Increment Incubated India 's Indiana manufacturing Indianapolis Indic Indication restriction Indolent Non-Hodgkin Lymphoma InduPro Infectious Canine Hepatitis Inference Infinity Bio Infinity Smart platform InflaRx Inflammatory Influence Inhalation Solution Inhaler Inhibikase Inhibikase Therapeutics Inhibitor Discovery Inhibrx Biosciences Inia Initiative Injury due to exposure to external cause Injury of cornea Innovaccer Innovate UK Innovative Health Initiative Innovative Medicine Innovent Innoviva Inovio Pharmaceuticals Inozyme Insight Insilico Inspira Technologies Instill - dosing instruction imperative Instrument - device Insurance Coverage Insurance Premiums Intas Intel INTC Intellidrop Intelligence Engine Intent Biologics Intercept Pharmaceuticals Interdisciplinary Studies Interim report Interius BioTherapeutics Interleukin-15 Interleukin-2 Interleukin-23 Subunit p19 International Aspects International Drug Prices International Recognition Procedure Interoperable Interpretation Process Interventional Urology Interventional procedure Interventional radiology Intervertebral Disc Degeneration Interview Intestinal Failure IntraBio IntraBio Ltd. Intranasal approach Intravascular Invasive aspergillosis Invest Europe Investigational Invivyd Ionis rivalry Iovance Biotherapeutics Iptacopan Ireland Iris (Eye) Irish healthcare Ironwood Isaralgagene civaparvovec Iscartrelvir hydrochloride Islatravir/lenacapavir IsoDDE IsomAb Isotope Technologies Isotope Technologies Munich Italy Italy antitrust probe Biogen Italy health service Itvisma Ivory Ixchiq vaccine Ixiaro Ixo-vec Izervay J.P. Morgan JADE101 JAGX JAK/SYK inhibitor JAK1 Inhibitor JAK1/TYK2 inhibitor JAM JAMA Dermatology JAMA study JBIO JC Virus JCV JN.1-lineage JNJ JNJ-2113 JNJ-4804 JPM Healthcare Conference JPMHC JPY JS005 JSKN016 JSPR JUST-AAV Jack Phillips Jackson Laboratory Jacobio Pharma Jacqueline Corrigan-Curay Jade Biosciences Jaguar Gene Therapy Jaguar Health Jake Leach Jake Van Naarden James Jamie Jamila Jan Hillson Janssen Vaccines January 2026 Janus kinase 1 Janus kinase 2 Januvia Janux Therapeutics Jardiance Jason Litten Jasper Therapeutics Jeavons syndrome Jeff Knight Jeffrey Venstrom Jeito Jeito II Jeremy Levin Jeremy Shefner Jerome Jersey pharma Jersey site Jesper Jian Jiangsu Hengrui Jideytro Jigani Facility Jim Lang Jim O'Neill Jiwan Joaquin Job Development Job Market Jodi Ungrodt Joe Biden Joe Rogan Joe Willey John Carroll John Moolenaar Johnson Johnson & Johnson Intra-Cellular Johnson COMP360 Definium DT120 psychedelic Johnson Joaquin Duato Joint Atomic Model Joint Ventures Jonathan Arambula Jonathan Vigdorchik Jonmark Jorge Bartolome Julie Kim July 23 July 29 Juncos June June 11 June 18 2026 June 2026 June 4 Junshi Justice Jackson Juvenile Juvmo K Pro K-554 K261580 K261916 KALOS KARD KARDIA-3 KARDINAL trial KAT5 wt Allele KAT6A degrader KB801 KDIGO KEAP1-mutant KER-0193 KEYNOTE-671 KEYNOTE-689 trial KEYNOTE-B96 KEYNOTE-B96 trial KINECT-DCP KIR-CAR KIT KKR KLKB1 gene KMT2A gene KO-7246 KOASTAL-2 KOASTAL-3 KOL Insight KOL Insight HR+/HER2- KOL Insight Psoriatic Arthritis KOMET-017 KP-301 KP-402 KP-701 KP.2 strain KPI-012 KPV KQ Labs KRAS inhibitor KRAS-driven tumors KRAS-mutant cancers KRAZATI-12 KSI-501 Kaerus KaiSR Kailera Therapeutics IPO Kainova Therapeutics Kakao Healthcare Kaken Kala Bio Kallyope Kalohexis Kane Biotech Kankakee Illinois Kansas City cardiomyopathy questionnaire Kanzun Ventures Kanzun-ARCB Growth Fund Kaposi 's sarcoma Kappa-Opioid Receptor Kardigan IPO Karen Massey Karen Smith Karin Conde-Knape Karoo Health Kashiv BioSciences Kate Estep Kate Walsh Katherine Szarama Keir Starmer Keith Keith Vendola Keloid Kelun Ken Paxton Ken Song Kendall Square Kennedy 's Kenneth W. O’Keefe Keren Leshem Kerry Dailey Kestrel Ketones Kevin Hardage Kevin Lobo Keystone Symposia Keytruda Qlex Keytruda SC Keytruda bladder cancer Keytruda combo Keytruda combo kidney cancer Keytruda head-to-head trial Keytruda patent Khalid Nabilsi Khartis Therapeutics Khosla Ventures Kidney Kidney Failure Kim Kin-Hung Peony Yu Kinase Assay Kits Kinaset Kinevant Kira Pharmaceuticals Kit device Kite Pharma partnership Kite, device (physical object) Kither Biotech Klaas Zuideveld Kleinbasel Kleiner Knee pain Kong Kong stock exchange Korea Korea market Korean language Kosmos Kostaive Kowa Kristin Bittenbender Kriya Kronos Kronos Bio Krystal Biotech Kumquat Biosciences Kv7 Kv7 activator Kv7 potassium channels KwikPen Kyle LaHucik Kymera Therapeutics Kyntra Bio LAG-3 immunotherapy LAGOON trial LAPSCOVERY LAVA-1266 LBL-024 LBP LBS-008 LDLR gene LEAD platform LEAP District LEAP2MONO LENZ LFMD LG Chem oncology China cancer LGBTQ+ professionals LGMD2I/R9 LGVN LIDE LIFE-001 LIGAND-AI LITESPARK-011 LITESPARK-022 trial LITFULO LLM-based technology LLMs LMT15 LNTH-2501 LONP1 gene LOTIS-5 LOTIS-7 LP.8.1 sublineage LPAR1 gene LR-MDS LRP4 gene LRPAP1 gene LRRK2 gene LSCD LSD therapy LTBR agonist LTGO LUCE-1 LUCIA trial LUCIDITY trial LUMINARA LUMUS LUNA 3 trial LX9851 LaNova Medicines Labor (Childbirth) Labor Unions Laboratory Animal Science | View Recording Lac-Phe Lakefront Biotherapeutics Lancet Landscapes Lansing Michigan Lantheus Holdings Larix Lark Health LarkVantage Lars Rebien Sørensen Larsucosterol Lasting Health Starts Latex Fixation Tests Latitude PsO Launch-HTN Lavandula Laverock Therapeutics Lead-212 Leaders resign Leads Biolabs Leads Biolabs ’ Leaked Leaking Lean Derisking Leapfrog Bio Lebanon Leber congenital amaurosis-4 Left atrial pressure Left ventricular ejection fraction Legal Case Legal Challenges Legend Biotech Somerset Raritan Legendary Peptides Lehigh Valley Lens platform LensAI Lepodisiran Leqembi IQLIK Lesion Lesion reduction Letitia James Leukoencephalopathy, Progressive Multifocal Leukopenia Levels (qualifier value) Lewy bodies Libertas Bio Libertyville Illinois License Agreement Life Life Biosciences LifeMine LifeMine Therapeutics LifeSignals LifeX Lifespan Extension Lifetech Lifyorli Ligand Pharmaceuticals Light AI Ligufalimab Lilly 's Lilly Buys 20B+ 2026 Lilly Jaypirca pirtobrutinib Lilly Novo Nordisk Lilly Verve buyout PCSK9 therapy Lilly inks Lilly obesity Lilly oncology chief Lilly retatrutide Phase 3 Lilly triple agonist FDA LillyDirect customers Limbal Stem Cell Deficiency Limitation Limited stage (cancer stage) Linac QA LinusBio Lionel Seltz Lipfendra Lipid Metabolism Disorders Lipids Lipoidosis Lipomatosis, Multiple Symmetrical Liposarcoma, Dedifferentiated Liquid CDx Lisa Eli List Litespark Lithotripsy Live - Specimen Condition Live Biotherapeutic Product Liver Cirrhosis Liver damage Ljubljana LoAc Loan Logica Logos London Bioscience Innovation Centre London Cancer Lone Star Peptide Long-Term Strategy Longeveron Longwood Fund Loop Lorbrena Lorundrostat Losers Loss of job Lotte Low dose Lower Profile Lower Rates Lp(a ) drug Lp(a)HORIZON Lucia Lukas Braunschweiler Lukácsháza Luma <eudicots> Luma Health Lumateperone Lumina 3D Lumryz Lumvoa Lumvoa FDA Lumykras LunAIRo Lung Diseases, Interstitial Lung consolidation Lung-201 Lunit Lunit AI Lunit SCOPE Lunsekimig Lunsumio-Polivy Lupinus Lupus treatment Lyell Immunopharma Lyfgenia Lymphatic Abnormalities Lymphocyte Count measurement Lymphocytes Lymphocytes, Tumor-Infiltrating Lymphohistiocytosis Lynavoy Lynk Lynozyfic Lyophilized Inactivated Group A Streptococcus TARA-002 Lyrfigtu M Ventures M financing M growth fund M&A consolidation M&A oversight M&A transactions M&amp M-TEER M.D. M1 receptor antagonist M1/M4 agonist M6495 M9466 MAA (Microalbumin aggregate albumin) MACE-3 MAGNITUDE-2 MAP4K1 gene MAR002 MASLD MATCHING MATTERHORN trial MC3R/MC4R MC4R MCD test MDASE MDD MDM2 Antagonist ASTX295 MDM2 gene MDNA11 MDNA113 MDR MDR CE Mark MDRI MEERKAT trial MEK inhibitor MER511 MESA MET exon 14 skipping mutation MET protein MFLUSIVA MGAT2 gene MGnify Stability Dataset MICSI-PET MIPOGA MIPSA technology MIRACLE trial MIT MITIGATE trial MK-3000 MK-7240 ML-007C-MA MLTX MMRV vaccine MOG antibody disease MONARCH-E MR closure MR-139 MR-L45 MRCT MRI-guided enhancement MRM Health MS MS drug MSH5 gene MST brand of morphine sulfate MST-0312 MTLE MTX240 MTX652 MVM MW101 MWT MYB transcription factor MYO7A gene MYR301 MZE829 MaGic trial MacTel Macao Machado-Joseph Disease Machine Macular degeneration Macular retinal edema Madness Madrigal Magnet <device> Magnetic Seizure Therapy MagnetisMM-5 Magnetocardiography Mahery Mainland China Maintenance dose Maintenance study Maintenance therapy Makary era Maker (occupation) Malaysia Malignant Bone Neoplasm Malignant Female Reproductive System Neoplasm Malignant Pleural Mesothelioma Malignant neoplasm of cardioesophageal junction of stomach Malignant neoplasm of gastrointestinal tract Malignant neoplasm of skin Malignant neoplasm of thyroid Malignant tumor of colon Malus domestica Mammals Manfidokimab Manic Manifold Bio Manihot esculenta Mantelli Manufactured Supplies Manufacturer Manufacturing costs MapLight Marburg Marcel Reichen Marco Rubio Marea Marengo Maria C. Freire Marietta Pennsylvania Marinesco-Sjogren syndrome Marjan Farid Mark Hammond Mark McLellan Mark Pavao Mark Stevenson Mark Turco Markers (device) Marketing Marketplace Martes pennanti Martin Martin Makary Marvell Technology MRVL Mary-Elizabeth Mastermind Platform Mastocytosis, Systemic Matchpoint Therapeutics Maternal Health Matrix Pharmaceutical Inc. Matt Buckham Matt Skelton Matwings Maxim Group May 18 May 2026 May 26 Mayne Mazdutide McKesson Measurement Measuring ruler, device Mechanism (attribute) MedQA MedSurg MediKarma MediView MediView XR MediView XR90 Medicaid block grants Medicaid fraud Medical Advisory Board Medical Affairs Medical Communications Medical Countermeasures Medical pathologist Medicare Part B Medicare coverage Medicare drug prices Medicare fraud Medicare reforms Medicenna Medicine Medicines Australia Medicines Discovery Catapult MedisourceRx Medivis Medline Medtronic Megadeals Megarounds Meister Melanie Ivarsson Melanocortins Melanoma TRP2 CTL Epitope Vaccine SCIB1 Meleda Disease Membranous glomerulonephritis Memo Therapeutics MenABCWY Menarini Menopausal symptom Menstrual migraine Menstruation Mental association Mentari Therapeutics Mentorships Merck 's Merck AbbVie Eli Lilly Pfizer Myers Squibb China Merck Verona Merida Biosciences Mersana Meta Metagenomi Metals Metapneumovirus Metastatic malignant neoplasm to brain Metastatic melanoma Metastatic to Metis people Metric (substance) Metriport Michael Bierl Michael Burgess Michael Chou Michael Houghton Michael Kott Michael Langer Michael Rogers Michael Severino Michelle Xia Microarray Analysis Microbial Microbiome SER-155 Microbiome therapeutics Microbiome-derived Peptide Vaccine EO2463 Micron Biomedical Micron Technology Microsoft Discovery Microsoft Teams Microstructure Imaging Microvillus inclusion disease Miels Mikael Mikael Dolsten Mikaela Naylon Give Kids a Mike Hershkovitz Mike Sciandra Mike Stuart Mild cognitive disorder Military Hospitals Milky Way Investments Millimeters of Aluminum Equivalents Miltenyi Biopharma Mim8 Mimrylo MindWalk Holdings Corp. Minder system Mindpeak MinervaX MingMed Biotechnology Minghui Minimal Residual Disease Negativity Mining Ministry of Health Minxiang Zeng Mirador Mirador vasculitis Mironid Mirum Misleading Drug Ads Missing Mission Therapeutics Mitchel Berger Mitigation Strategy Mitochondrial Diseases Mitral valvuloplasty Mitsubishi Mitsubishi Tanabe Pharma Mixed readout MoSEIC Mobile Health Mochida Pharmaceutical Modality Modeling Moderna vaccine facilities Modernization Modeyso Modic Moffitt Cancer Center Mohammed Moist Molecular Clamp technology Molecular Gates Molecular Targets Molecular stability Moleculin Momentis Surgical Monarez Monitoring Systems Monte Montes Montgomery County Month of May MoonLake Immunotherapeutics Moonwalk Biosciences Morbidity - disease rate Morgan Morgan Stanley MorphoSys Morristown Mosliciguat Mosunetuzumab Motion Mourenx Movantik Move GBS Forward™ Movement Mprosevir Mucopolysaccharidosis I Mucopolysaccharidosis III Multi-Drug Resistance Multiomics Mumps Mundipharma Munich Regional Court Mural Mural Oncology Muscarinic Agonists Muscle Tissue Muscle function Muscle strain Muscle-Boosting Drugs Musk MyHealth app MyLabcorp MyOme MyPhenome Mycobacterium tuberculosis Myelin Sheath Myeloid Progenitor Cells Myers Squibb collaboration Myositis Myricx Bio NAVSUNLI NBI-1070770 NCT07153536 NDA China NDA filing NEO100 NEPTUNUS-1 NEPTUNUS-2 NFX NGAL NGM NGN-401 NGS NHS NHS England NHS trial NHS-Galleri NHS-Galleri trial NIH grant NIH layoffs NIH-funded NINL gene NIO NK1/NK3 receptors NKTX NLRP3 inhibitor NMPA NMTi NON Mouse NOR-101 NOS1 protein, human NOVA NOVI NP-MP1 NPDR NPM1 gene NPM1-mutant NR1H4 gene NR4A2 gene NRG NRG1 gene NRTX-1001 NSCEB NTHI NTLA-2002 NUCLIDIUM NUSAP1 gene NUZ-001 NVG-291 NVIDIA 's NVIDIA Lilly NX-3911 NX210c NYU Nabla Bio Nach01 Namandjé Bumpus Nanexa NanoDisc NanoPhoria Nanobody Discovery Platform Nanomedicine Nanostructured Materials Naphthoquinones Nasal Polyps Nasal drug delivery Nasal inflammation Nasdaq Stockholm Nasua Natalia Misciattelli Natera National Association of National Biotechnology Conference National Cancer Institute National Priority Vouchers National Resilience National Security Act Native (qualifier value) Natural Natural Capital Natural History Study Natural killer triggering receptor, human Natural-history studies Nature Nature Aging Nature Biotechnology AI biology Nature Biotechnology Nanovials Nature Biotechnology billion Nature Biotechnology cell-cell interaction Nature Medicine Nausea Nav1.8 inhibitor Nav1.8 inhibitors NeOnc Technologies Nebulizers Negative Predictive Value of Diagnostic Test Negotiation Program Neko Health Nektar Nelson Sun ; Chief Operating Officer Nemluvio Nemvaleukin Alfa Neo-1 Neoadjuvant Therapy Neoantigen Neomorph Netherton Syndrome Neumora Therapeutics NeuraClick Neural Circuit Stimulation Neural Network Simulation NeuralPLexer Neuro Disease Neuro-ophthalmology NeuroQuant NeuroThera Labs NeuroX merger Neurogene Neuromedin K Receptor Neuromuscular Monitoring Neuromyelitis Optica Neurona Therapeutics Neuropsychology Neurosteroids Neurotrophic keratitis Neutrophil Elastase Inhibitors Nevada Nevada <Geographic Area> New Approach New Approach Methodologies New Jersey layoffs New Jersey operations New York AG New York City New York Stock Exchange NewAmsterdam NewBridge Pharmaceuticals Newborn NewcelX Nexon platform Nexplanon Next Pathways NextCure NextGen NextRNA Nextstellis NiKang Therapeutics Nia Tatsis Nick Eshkenazi Nick Vatakis Nicole Ossey Nicole Verdun Nimacimab Nimble Nimbus Niowave Nippon Shinyaku Nominee Non-Hormonal Non-Incretin Non-Muscle Non-Opioid Non-Opioid Pain Nona Biosciences Nonalcoholic Steatohepatitis Nonclinical Automation Noninvasive Endpoint Nonsense mutation Noom Nordisk alliance Nordisk facility Normalize (activity) North Chicago North Chicago Illinois North Immunology North Star Ambulatory Assessment Clinical Classification Northern District Northwest Nosis Novartis ' Vasant Narasimhan Novartis Venture Fund Novartis-Chinook acquisition November 2025 Novo Holdings Novo Nordisk Plainboro NovoCare Novocure Nubeqa Nucleus RadioPharma Nulibry Numab Numerous Nura Bio Nurses Nutrition Guidelines Nuvalent buyout Nuvation Nuvation Bio Nuzolvence OAKH OASIS poly(divinyl-co-N-vinylpyrrolidinone) OASIS-5 OBI OBT OBX-115 OCT50 OCU400 OCU410 OFA OHB-724 OHSU OIG bulletin OKYO OM336 OMass ONS-5010 ONTARGET ONWARD OPKO OPN1MW gene ORBIT trial ORKA-001 ORM-1153 ORM-6151 ORN-252 ORNITHINE CARBAMOYLTRANSFERASE ORX142 ORX489 ORX750 OSE Immunotherapeutics OTX-201 OTX-TKI OVATION OX2R agonists OX40 receptor OX40L antibody OXPHOS pathway Oak HC Oak Hill Bio Oberland Capital Oberon Obesity Drugs Obesity Trial Obsessive compulsive behavior Obsidian Therapeutics Ocaliva Occupational activity of managing finances Oceanside Ocedurenone October Ocugen Ocular Therapeutix Oculis OdyssION platform Officer David Rose Offit Ogilvy Health Olatorepatide Omeros Corporation Omicron Omicron JN.1 OmniAb Omnipod Omnitrope Omniverse On-Demand Events Onapgo Once a day, at bedtime Once-Weekly Insulin OncoMimics Oncoinvent ASA Oncologic Oncology & Multispecialty Oncology Collaboration Oncology Focus Oncolytic Viruses Oncotelic Therapeutics Onswik Opakalim Opamtistomig OpenEvidence Operable Brain Tumors Operating Operating expenses Operation Access Operation Trailblazer Operational streamlining Operator Partners Opfolda Ophthalmological implant Opiate Addiction Opioid Opioid Crisis Opioid Use Disorder Opportunity Fund III Opthea Opthea 's Opthea layoffs Optigo Biotherapeutics OptimiZe technology Optimism Optinose Optogenetic Gene Therapy Opvee divestiture Opzelura Oracle Health Oral Medication Oral Wegovy Orals OrangeDot Orano Orbis Orbis Medicines Orbital Therapeutics Orca-T. Order Tubulidentata (organism) Organ Shortage Organisation for Economic Co-Operation and Development Organizational Culture Organovo Ori-C101 Oricell Therapeutics Orion Group Orna Therapeutics Orotecan Orpathys Orphan Cures Act Oruka Oryon Cell Therapies Osanni Bio Oscotec Osivax Oslo Stock Exchange Osteogenesis Imperfecta Osteoporosis Ostro acquisition Otsuka 's Otsuka Holdings Ottava Oura Genomics Oura Ring 5 Outfront Health Outlook Therapeutics Outlook Therapeutics ' Outsourcing Ovation.io Overall Publication Type Owkin Ownership Oxervate Oxford BioTherapeutics Oxford Finance Oxford spinout Oxycontin Oyster Point P&G P-Value PACAP X CGRP bispecific PADOVA study PALSONIFY PARP1 PATHFINDER PB212 PBA PBC PBH PBLS PBMCs PC Platform PCED PCSK9 base PCVs PD PD-1/VEGF bispecific PD-1xVEGF bispecific PD-L1-high PD-L1-negative PD-L1xVEGF-A PDE4 inhibitor PDS0101 PDS01ADC PDS0301 PDUFA VIII PDZ domain PER-001 PERC PERIDOT PERSEUS trial PET/CT scan PF-06954522 PF-07872412 PF-ILDs PFAS gene PG-102 PGI PGN-EDODM1 PH-HFpEF PH-ILD PHD inhibitor PHVS PHocus trial PI3 K inhibitor PI3 K inhibitors PI3 K pathway PIK3CA-driven PIK3CA-mutant PIK3CA/AKT1/PTEN mutations PIK3CA/AKT1/PTEN pathway PIKTOR PIP financing PIPE financing PIVOT-PO trial PK activator PKMYT1 protein, human PKP2-associated cardiomyopathy PMA PMN310 PNH drug development POETYK PP353 PPF PRA023 PRC2 inhibitor PRECISE-AD trial PREVAIL trial PRISM BioLab PRMT5 gene PROGRESS-AD PROSERA PROTACs PRT13722 PRV PRX012 PSMA PSMA-targeted radioligand therapy PSMA-targeting PTAB PTEN-deficient tumors PTH1R gene PTK7 PTK7 protein, human PTRS PURPOSE studies PYNNACLE trial Pacira Pacira BioSciences Pain Palleon Palsonify Paltusotine Palynziq Pancreatic Ductal Adenocarcinoma Pandion Panorama study Paolo Tarantino Papillary Disease Papillon Parabilis Paratek Parker Institute for Cancer Immunotherapy Parkinson Parkinson 's Part B drugs Participant Particulate (substance) Partner Therapeutics Partnering Partnering Office Pasadena Pasatru Pascal Soriot Passage Bio Path-IO Patient Care Team Patient Engagement Patient Flow Patient Protection and Affordable Care Act Patient Reported Outcome Patient Square Capital Patient data Patient education (procedure) Patient location type - Department Patient-Centered Patrick Vink Patrizia Cavazzoni Patsnap Patterns Paul Chaplin Paul Edick Paul Fornazzari Paul McKenzie Paul Thomas Pavblu Payer Engagement Payspan Pazdur Peakbridge Pediatric care Pediatrics Pedro Beltran Peeling of skin Peer-Reviewed Research Pegunigalsidase alfa Pelage Pelage Pharmaceuticals Pemgarda Pemphigus Pemphigus Foliaceus Pendred's syndrome Pennsylvania site closure Pensions Pentagon Pentagon blacklist PepGen PepMetics Peptide API Perception Perianal fistula Peripheral Arterial Diseases Peripheral neuropathic pain Peripheral neuropathy due to and following antineoplastic therapy Perjeta Perkins Perl50 Permanent Peroxisome Proliferator-Activated Receptors Persica Persistent Personal Data Engine Personality Character Perspective Perturb-seq Peter Greenleaf Peyronie 's disease Pfizer 's Pfizer Albert Bourla Pfizer Andrew Baum Pfizer Astellas Padcev Pfizer Ventures Pfizer acquisition Pfizer staff Pfizer vet Pfizer walk away Pfizer-BioNTech Phagocytosis Pharma Acquisition Pharma Concessions Pharma Manufacturing Pharma Tariffs Pharma import taxes PharmaShell Pharmaceutical Ingredients Reserve Pharmaceutical Investment Oversight Pharmaceutical Layoffs Pharmaceutical Packaging Pharmaceutical Policy Pharmaceutical executive pay Pharmacogenomics Pharmacy Compounding Advisory Committee Pharmatech Pharvaris Phase 1 - 2a Phase 1 Data Phase 1 trials Phase 1/II Phase 1b/2 Trial Phase 1b/2a Phase 2 BEACON Phase 2 Failure Phase 2 HORIZON Phase 2 TRAILHEAD Phase 2 VALIANT Phase 2 data Phase 2 results Phase 2 termination Phase 2a Phase 2a Trial Phase 2b SYMMETRY Phase 2b trial Phase 3 Alkivia study Phase 3 Breast Cancer Trial Phase 3 COMPETE trial Phase 3 CREST trial Phase 3 HAELO Phase 3 INDIGO Phase 3 INDIGO trial Phase 3 PIVOT-PO trial Phase 3 RINGSIDE trial Phase 3 SENTRY trial Phase 3 SURPASS-IPF trial Phase 3 confirmatory trial Phase 3 development Phase 3 induction Phase 3 planning Phase 3 plans Phase 3 program Phase 3 prospects Phase 3 readiness Phase I – III study Phase I/II study Phase II Failure Phase II SANRECO Phase II data Phase III AURORA trial Phase III ENERGY 3 trial Phase III Essence study Phase III MAGNITUDE trial Phase III MARIPOSA trial Phase III REGENCY trial Phase III ReSPECT trial Phase III SCLC trial Phase III ZENITH trial Phase III desmoid tumors Phase Ib/II trial Phesi Philadelphia Semiconductor Index Philip Brainin Phoenix Arizona Phosphodiesterase Type 4 Photoimmunotherapy Physical AI Physical Examination Physical activity Physician Executives PiNACLE Piclidenoson Pilatus Pill Penalty Pilot Projects Pimurutamab Pinnacle Medicines Pioneer Antibody Discovery Pioneering Medicines Pipeline Review Pipeline Strategy Pitch - substance PitchBook Pivotal Pivotal Trial Pixel Watch 5 Plainsboro New Jersey Plants Plaque (lesion) Plasma Playground Global Plenary Session Plenary Speakers Plexiform Neurofibroma Pliability Plozasiran Pluri Pluvicto challenger Pneumococcal vaccine Pointillist platform Poisons Pol Theta Polaryx Therapeutics Polivy Polpharma Biologics PolyPeptide Group AG Polycystic Kidney, Autosomal Dominant Polyradiculoneuropathy Pombiliti + Pooled Sample Portal Biotechnologies Portfolio diversification Positive Opinion Positron-Emission Tomography Post-Exposure Prophylaxis Post-Pandemic Downsizing Post-bankruptcy consolidation Post-marketing study Potentials, Event-Related Praluent Prasad 's Prasinezumab Pre-Consult Precision Pre-Eclampsia Pre-Exposure Prophylaxis Pre-filled Syringe Prealbumin Precision Diagnostics Precision Imaging Network Precision Medicine Group PrecisionLife Predetermined Change Predict Pregnanolone Preliminary diagnosis qualifier value Prelude Therapeutics Premarket Approval Premier Inc. Prescription Drug Overuse Prescription Fulfillment Presidential Symposium Preventive Health Programs Prevnar Primary Primary hyperoxaluria Primary sclerosing cholangitis Prion Diseases Private financing Privigen Privosegtor ProMIS Neurosciences Proactive Health Probiotics Probody Platform Processa Pharmaceuticals Professional guide Profiling (action) Profluent Progestins Projections Prologue Medicines Prometheus Prometheus Biosciences Promoter Score Promotional Claims Prompts Propel Propensity Score Prostate-Specific Antigen Prot-MaP Protara Therapeutics Protein Kinase C Protein Kinase C Inhibitor Protein Overexpression Protein Purification Protein Stability Protein, Organized by Structure Protein-Protein Interaction Proteome Protillion Biosciences Proto-Oncogene Proteins c-akt Protoporphyrin IX Provider Provider Services Proxi Biotech Proximity Prurigo PsA-2 trial PsCatCh2.0 Pseudobulbar affect PsiThera Psoriasis of scalp Psoriatic PsyLabs Psyence BioMed Ptarmigan-1 Public Health Trust Public Listing Puerto Rico Pulmonary Eosinophilia Pulmonary artery pressure Pulmonary veins Pulmovant Pulse intelligence engine Purchase Purchased Services, Clinical and Biomedical, Calibration, Laboratory Purchased Services, Clinical and Biomedical, Research Purchased Services, Staffing, Supply Chain Purdue PureTech PureTech Health Purity Purpura, Thrombotic Thrombocytopenic Pushechnikov Put Option Agreement Pyelonephritis Pyoderma Gangrenosum Pyzchiva Q-Scientist Q1 trends Q126 Q2 layoff Q2 sales Q3 2026 Q32 Bio Q4 FY2025 QA QA102 QCS QIAsymphony QLS-111 QNRX QRS prolongation QRX003 QT Imaging QTORIN rapamycin QTTB QUC398 QULIPTA QURE QWINT Qatar Qilu Pharmaceutical Qlaris Bio Qlex QuEEN Qualification QuanBio QuantHealth Quantitative (qualifier value) Quantitative Continuous Scoring Quantori Quest Analytics Question (inquiry) Qulipta Quoin Pharmaceuticals Quotient Therapeutics Qureight Quviviq R&D chief R&D cleanup R&D frontier R&D hiring Q2 2026 R&D shutdown R&D strategy R&D strategy shift R0 completely resected RACC RAS cancer RAS-addicted cancers RAS-mutated RAS/RAF inhibitor RASolute 302 RBM39 gene RCQ RCT RDX-002 RE104 REACH-DMD study REACtiVe-2 REDEFINE-4 weight loss REGENERATE-PD REGN7041 REIMAGINE 5 REM-422 RENOIR RESTORE-FA RESTORE-PV RET Inhibitor RET protein, human REVEAL-1 REZOLVE-AA REZOLVE-AD RFK Jr. rhetoric RFK Kennedy RG6496 RGI-C scores RIDDL RIFs RIGL RIPK1 protein, human RIPK2 RIPK2 scaffolding inhibitor RISE3 RLTs RMTX RNA Vaccine RNA delivery RNA drug RNA exon editing RNA gene RNA medicines RNA obesity RNA technology RNA test RNA therapies RNA-LNP RNA-targeted medicine RNA-targeted therapy RNA-targeting RNAi medicine ROR1 protein ROR1 protein, human ROS1-positive ROS1-positive Lung Cancer ROS1-positive NSCLC ROSA Knee ROSELLA trial RP1 melanoma RPE cells RPTR-1 RQ Bio RQB01 RRP RS- RSNA RSV antibodies RSV vaccine RTU cartridges RV-8451 RVO RVU120 RVUs RWE RXFP1 gene RXIM002 RXRX RZLT Race:Type:Point in time:^Patient:Nominal Rachael Racism Radar Therapeutics Radiance Biopharma Radicava Radiology Specialty Radiometry Radionuclide therapy Radiopharmaceutical Manufacturing Radspherin Rahway Raised Rakuten Medical Rallybio Rallybio RLYB212 Ramp Rancho BioSciences Randomized Controlled Trials as Topic RaniPill RaniPill ® Capsule Ranluspec Ranluspec Lucentis Ranluspec ranibizumab-hkdz Ranluspec vials Rapid Edge Cloud RapidAI Rare Disease Endpoint Advancement Ratio Therapeutics Ravi Thadhani RayThera RayzeBio ReFocus trial Readiness Reading (activity) ReadyFlow Autoinjector Rebate Model Rebeca Villarreal-Barragan Receptivity Receptors, Islet Amyloid Polypeptide Reciprocal Reclassification Recludix Pharma Recognify Life Sciences Rectal Carcinoma Recurrence Risk Recurrent ovarian cancer Redx Pharma Reflex Refractory Plasma Cell Myeloma RegCell RegFlow Regeneron Pharmaceuticals Regeneron Warren Regulation of biological process Regulators (device) Regulatory Authority Regulatory Crackdown Regulatory Expertise Regulatory Framework Regulatory Impact Regulatory Path Regulatory Pathway RegulatoryFlow Reindeer Reinvent Reinvention Relapsed/Refractory Relative (related person) Relaxin Relay Device Relay Therapeutics Relief Therapeutics Relieving Religious Missions Relmada Relyvrio RemeGen partnership Remepy Remix Therapeutics Remote Internship Remote control command - Clear Renalys Rentschler Rentschler Biopharma Repair of ventral hernia Repare Reperio Health Repligen Research Alliance Corporation III Research Organization Research Triangle Park Reshma Kewalramani Resolve platform Resources Respiratory Distress Syndrome, Adult Respiratory rate Response Evaluation Criteria in Solid Tumors Restricted Resume - Remote control command Resumption Retension Pharmaceuticals Retifanlimab Retinoschisis Retreatments Retro Biosciences Retrotransposons Return on Investment Return to (contextual qualifier) (qualifier value) Reunion Island RevMed Revenue Milestone Reverba Global Reverse Stock Split Review Voucher Revita Reviva Pharmaceuticals Revolution Vibe CT Revolution daraxonrasib Revuforj Reykjavik plant Rezatapopt Rezolute Rezon Bio Rezurock Rezzayo Rhythm Ribo RiboX Ribupatide Richard Richard Fair Richard Gonzalez Richmond Rick Fair Rick Osterloh Rickets Ridgefield New Jersey Riliprubart Ring Sideroblast Status Rinvoq growth Ris-Rez Risdiplam Rise Up trial Risk Reduction Ritlecitinib Rivus Pharmaceuticals Rob Michael compensation Rob Pinataro Robert Kramer Robert Malone Robert Michael Robert Warner Roche 's Roche Diagnostics North America Roche Tecentriq Roche subsidiary Rocket Pharma Rocket Pharmaceuticals Rocklin Lab Rockville Maryland facility Roctavian Roger Perlmutter Roivant Sciences Rolvedon Ron Renaud Ronald A. Williams Ronde-cel Roopal Ross Haghighat Rotation Round three Royalty Pharma Royalty-Driven Model Rubella Ruby trial Rugonersen Russia Russian language Rx refill Ryan Richardson Ryvu Rznomics S&P SABCS25 SAFEbody technology SAFFRON SAIL-0839 SALT score SALT score * * SANDCAT trial SAR workflows SARC041 SARM1 Inhibitors SASAC SASS SASTIND SAVITRI SB-01 SB36 SBA SBT-77 SBX sequencing SC0062 SC451 SCAN disorder SCLC SCLT SCN10A gene SCN2A mutations SCOPE IO SCOPE trial SCOTUS SCY-247 SCYNEXIS SEALS trial SEC SEED Therapeutics SENS-501 SENTRY trial SEP-786 SERON SERP-01 SERPINA1 gene SGR-2921 SGT-003 SH2D1A gene SHASTA-3 SHASTA-4 SHORE SHP-DB1 SHTG SIK2 gene SIM0505 SIM0709 SION-2222 SION-451 SIRP antibody SITC SKB105 SKIA SKYWAY SLC17A5 gene SLTE SLTE-1009 SLV-154 SLV-324 SMA SMARCA2 protein, human SMN2 gene SNDK SOHO SOL-1 SOLAIRIA-1 SOLAIRIA-2 SOV SPAG8 gene SPG302 SPR720 SPR9644 SPRB SPY072 SPaL SR One SRI-4 SRP-1003 SRP-9003 SRSD107 SSGJ-707 ST-01156 STARLYS trial STARx STAT6 STAT6 protein STELLAR-303 trial STI-based STOMP2 STOP-V1 STOP-V2 ) STX-001 STX-1150 STXBP1 gene SUCCESSOR-2 SUNMO SUNY AI Symposium SURMOUNT-5 Trial SURMOUNT-MAINTAIN SURPASS-CVOT SURPASS-PEDS SVR35 SW-682 SYD-101 SYK SYNC-T Sabeen Mekan Sackler family SafeBeing platform Safety Data Safety Issues Safety labeling Sagava Sagimet Sahil V. Kirpekar Sailaja Battula Sales growth Salesforce Sam Roosz Samit Samsara Samsung Bio Samsung Bioepis Samsung Health Assistant Samsung Health app San Diego biopharma San Francisco San Rafael SanDisk Sana Biotechnology Sanacor Sangamo Therapeutics Sanjay Sanjula Jain-Nagpal Sanofi Blueprint Medicines Sanofi Efluelda flu Sanofi Strategic Sanofi acquisition Sanofi flu Santen Santé Ventures Sapablursen Sapio Sapio Sciences Sapu Nano Sapu003 Sapu006 Sarah Boyce Sarah Gheuens Sarbani Sarcoidosis, Pulmonary Sarcoma, Epithelioid Sasanlimab Sasineprocel Scaling Laws Scheme Scheme of Arrangement Schott Schweizerhalle SciSparc Science journal Science of Microbiology Science of Virology Science of genetics Scientific Context Scientific Data Scientific Sessions ScinoPharm Sciwind Sciwind Biosciences ScopeAI Scorpions Scott Howell Screens (device) Scribe Therapeutics Scripps Research Script Seagen acquisition Seattle Office Closure Section 301 Section viii Sector Security Institute Security Measures See-Mode Self-Injectable Self-Management Self-injection Self-pay Semcap AI Semerjian Senators Send (transmission) Senile cardiac amyloidosis Seno Medical Sensei Biotherapeutics Sensorineural Hearing Loss (disorder) Sensorion Sensorion hearing loss program Sentire Surgical System Senzime September 14 September 2026 Sequestration Seralutinib Serbs Seres Sergio Marullo di Condojanni Series A round Series B fundraising Series C funding Series D equity Series D1 Series E funding Series F financing Serif Biomedicines Serine/Threonine Kinases Serious Seronegative Sevaro Health Severities ShORe Shadow Shandong healthcare Shane Speirs Shankar Ramaswamy Shapes Shareholder Ownership Structure Shareholders Meeting SheMed Shehnaaz Sherwin Sattarzadeh Shield Shigella Infections Shigella Vaccines Shin Ashida Shingrix competitor Ships Shock Shooting sensation quality Shortened Sialic Acid Binding Immunoglobulin-like Lectins Sibel Health Sickle Cell Siemens Healthineers Signal Signal Transduction Signatera Silence Therapeutics ' Silver bunionectomy SimpleScreen Simplexvirus Simufilam Single Agent Therapy Single-Domain Antibodies Sionna Therapeutics Siran Biotechnology SiranBio Sirexatamab Sirius Sirona Medical Sitala Site Closure Site of exit Sjögren 's disease SkinJect Skindex-16 SkyEngine Skye Bioscience Sleep disturbances Slovenia Small Business Smart Health Map Smart contact lenses Smoldering myeloma Social Media Society for Neuro-Oncology Solid Biosciences Solstice Oncology Solubility Solutions Solve Therapeutics Solventum SomaLogic Somatix Somatosensory Cortex Sonia Sonoma Sotatercept Sotyktu BIOPHARMA Source South Korean biotech South San Francisco headquarters Southern Sotho language SpaceX Spago Nanomedical Sparrow Pharmaceuticals Spatial Mosaic Specialty pharma Specimen Spectral AI Spectrum Profiling Speed-to-Launch Barriers Spevigo Spine BioPharma Spinogenix Spiriva Respimat SpliceCore Spondylarthritis Spravato Spravato sales Spray Drying Spring Health Spruce Biosciences SpyGlass Pharma ( SpyLock technology SpyTag/SpyCatcher Spyre Therapeutics Squamous cell carcinoma Squamous cell carcinoma of skin Squibb Layoffs Squibb partnership Srikanth Pendyala Stable angina Stage level 4 Stanford research Staphylococcus aureus StarTrack3 Stargardt disease type 1 State Room Statement Status Quo Ste-Foy Steam Stein facility Stelara Decline Stemchymal Step (specific stage) Step Pharma Stephen Hemsley Stephen Hoge Stephen J. Ubl Stephen P. Dale Steve La Neve Steve St. Onge Steve Tomlin Steve Ubl Stevenage Stevenage facility closure Stimulant Stimulation procedure Stock Reaction Stoke Storm Therapeutics' Strategic Brands Strategic Deals Strategic Growth Strategy Stratify Dx Stratus Strensiq Stress Stress Fractures Striker Pharmacy Strive Pharmacy Structure Structure of hippocampal commissure Structure partnership Stryker Stuart Pharmaceuticals StudyHub Stéphane Bancel Subacute Care Subcutaneous Cancer Sublocade Subsidies Substance Abuse Detection Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance) Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) Success SunRISe-1 trial Suneet Varma Sunita Mishra Super Bowl 2025 Super Bowl ads SuperPOD Superficial ulcer Superluminal Medicines Supernus Supervisory Board Supply Chain Security Supply chain disruption Support Services Program Supportive care Supranuclear paralysis Supreme Court stay Surgeon Surgical Replantation Surgical Robot Surgical System Surgical transfer - action Surveillance: safety Susan Susvimo Sutro Suvretta Capital Management Suzanne Winter Swift Medical Swift Ray SwiftFluo Swissmedic Swixx Group Swoop Sword Health Sydnexis Sylvia Isler Symptomatic Symptoms score SynAIRgy SynKIR-110 SynKIR-310 Synapse AI Synbio International Inc. Syncromune Syncron-E Syndax Syndeio Syngene Synnovation Synthesis Syphilis, Congenital SystImmune System System User -- individual Systemic candidiasis T business T cell therapy T cell-targeted T-Bolt T-Charge T-DXd T-cell engineering T-cell malignancies T-cell reprogramming T-cell therapy TA-ERT TACR3 protein, human TACTI-004 TAF8 wt Allele TAILORED-AF TAK-279 TAK-921 TAS-205 TB Alliance TCEs TCGX TCR TCR-NK cell therapy TEAD2 gene TEAEs TECVAYLI TECregen TED TESARO TETON-2 TEV-408 TEV-53408 THB335 THETA platform THRIVE-2 TIDAL-01 TIGIT antibody TIL cell therapy TKI TKIs TL1A pathway TLN-121 TLN-254 TLN-372 TLR7/8 TLR7/8 inhibitor TLX2 gene TMP-301 TNF gene TNFSF13B gene TNGX TOGETHER-PsO TPRG1L gene TR-FRET TRANQUILITY trial TRANSCEND TRANSCEND-T2D-1 TRBV9 gene TRCN-1023 TRD TREX1 gene TRICORDER TRIDENT trial TRIM21 TRIMTAC TRIUMPH TRIUMPH program TRIUMPH-1 TRIUMPH-2 TRIUMPH-3 TRLN TRONTIER TROP2/HER3 ADC TRPC6 inhibitor TRPV4 protein, human TRVI TRex Bio TRiM platform TSHA-102 TSX TScan Therapeutics TTAM TTR TULIP-SC trial TV ad TV drug TYK2 TYK2 Inhibitor TYR wt Allele TYRA-300 Tace TaiGen Biotechnology Taiho Oncology Taiwan market Takeda FDA filing Takeda Pharmaceuticals Takeda Protagonist Therapeutics Takeda rusfertide Takeo Takhzyro Takings Taladegib Taltz Talus Bio Talzenna upstream data ASCO Tamarind Bio Tampa Florida Tanabe Pharma Tang Tanruprubart Tao Fu Tarja Stenvall Tarsus Pharmaceuticals Tassos Gianakakos Tautomer-Predictor Tavapadon Taxes Taysha Gene Therapies Tecan Tech Rivalry TechLive Technology Transfer Teclistamab Ted Love Tedopi Teijin Teladoc Health Telesis Bio Tempero Bio Tempus Tenax Therapeutics Tenpoint Therapeutics Tenvie Tepkinly Termination - Inactive Reason Code TerraBind Terremoto Terry Fox Research Institute Test Result Testiculo- TetraGraph Teva Pharmaceuticals Tevimbra Texas Facility Texas Peptides Texas Tech Tezspire Th17 cells Thad Huston Thakkar The Novo Way Therapeutic Antibody Therapeutic Genetics Therapeutic Index Therapeutic Mobilization Therapeutic radiology procedure Therapeutic tactile stimulation Thetis Study Thick ThinkSono Third Circuit Court Third Harmonic Bio liquidation Third line treatment Thomas Thomas Hartung Thomson Reuters Thousand Oaks Thrive Capital Thrombotic Microangiopathies Thrombotic Stroke Thrombus Thyme Care Thyroid Diseases Tidmarsh Tim Van Hauwermeiren Time Timothy Wentworth Tinlarebant Tinnitus Tiragolumab Titan Titania Titles Tivicay PD Tiziana Life Sciences Tokyo Stock Exchange Tomi Sawyer Tonix Tonmya Topaz trial Topco Tortugas Toru Ashida Total Improvement Score Tourette 's syndrome Tourmaline Bio Toxic Epidermal Necrolysis Toxic Oligomers Toxicology Trace Neuroscience TraceNET Tracer Tracy Beth Heg Traditional Medicine Trail Making Test Transcarent Transcranial magnetic stimulation Transdermal Route of Drug Administration Transfection Transformation Officer Transformational Data Transforming RNA Medicine Development Translational Oncology Transpher A trial Transplantation Transposition of Great Vessels Transthyretin Amyloid Cardiomyopathy Transthyretin related familial amyloid cardiomyopathy Trastuzumab Rezetecan Travel Health Treasury rules Treatment Adherence Treatment Effectiveness Treeline Biosciences Trevi Therapeutics TriNetX Trial Phase Trillion Gene Atlas Trinity (ethnic group) Tris Pharma Trixeo TruTCR TrueLab Biopharmaceutical Trump 's Trump administration reforms Trump administration tariffs Trump budget Trump floats Trump import tariffs Trump overhauls childhood Trump policies Trump tariff Trust (Social Behavior) Trutakna Truvada Truveta report Tsingke Tudriqev Tukysa Tumor Microenvironment Tumor Suppression Tumor board Tumor stage Tis Tumor-Infiltrating Tumorad-01 Tumorigenicity Tumour treating fields therapy Turbine Turitz Twist Bioscience Tyler Sloat Type A meeting Type II JAK inhibitor Type of bridge device Tyrosine Kinase Inhibitors [MoA] Tyvaso Tzield U-turn U.S. Dollar U.S. Food and Drug Administration U.S. Justice Department UCCD UK 's UK-US UNC13A gene UNLOXCYT UP-AA UPB UPCR US-China competition US-EU USP30 inhibitor USPTO USTR UgeneX Ultreon 3.0 Undetectable Unicorn births Unified - Type of Agreement Uninsured United Imaging Healthcare United Laboratories International Holdings Limited United States Agency for International Development Universal Universal Cells University of California University of Toronto Unixell Biotech Unlearn Unravel Unspecified Abortion UpToDate Expert AI Updates Upstream Bio Uptake Urate Transporter 1 Inhibitor Urcosimod Urinary Bladder Urinary hesitation Urine culture Urology Urticaria Urticaria due to cold Usher Syndrome Type 1B Usona Institute Utebzi Uveitis Uwe Buecheler V-01/OPA-100 trial axe VAD044 VAL-413 VALOR VALOR study VALOR trial VAV1 protein VAX-24 VAX-31 VAY736 VAYHIT2 trial VBDS VCT220 VDPHL-01 VEGFR-targeted therapy VELO VENT-02 VENT-03 VERIFY trial VESALIUS-CV trial VESPER-2 VHB937 VHH VHH Immunoglobulin Fragments VIKTORIA-1 trial VISTAS study VITALIZE VIZZ VLA15 VMAT2 Inhibitor VMS VMX-C001 VRDN-003 VWF wt Allele VX-993 VY1706 VY1706 gene therapy VY7523 VY9323 VYJUVEK Vabysmo slump Vaccination Hesitancy Vaccine Efficacy Vaccine Reform Vaccine Testing Vaderis Therapeutics Vadodara Vaginal Microbiome Valar Labs Valiltramiprosate Valinor Vamikibart Vanda Vanderbilt University Medical Center Vanrafia VantAI Variable (uniformity) Variation (Genetics) VarmX Vascular anomaly Vaseline Vasodilation Vasudev Bailey Vault Vaxcyte VectorY Vedana Therapeutics Veeva Systems Vega Therapeutics Veklury VelaVigo Vemircopan Ventana Medical Systems * * Venture Exchange Venture House Venture Lab Ventures Verastem Veraxa Verge Labs Verification Verily Verily Me Verismo Therapeutics Versant Vertex Veru Vesta <beetles> Vestibulo-Ocular Vevzuo ViVac Pharma Viatris Vibrance-1 study Vicebio Vidofludimus Calcium ViewPoint EchoPilot Viewer Device Vigil Neuroscience Viking Global Investors Villya Pharmaceuticals Vimseltinib Vinay Prasad FDA memo Vincentage Vincentage Pharma Vineet Agrawal Violence Violet AI Viome Viral Viralgen Virginia Virginia facility Virginia plant Virtual Cell Model Virtual Geneticist Virus-Like Particle Visible Vision Restoration Vistagen Visual Suppression Visugromab Vitor Roque Vitruvian Partners Vitruvias Therapeutics Vivek Ramaswamy Vivtex Volatility Voluntary Scheme Vor Bio Voucher VoxNeuro Voxzogo hip injuries Voyage study Voyage trial Voyager Therapeutics Vunakizumab Vyglxia Vyondys 53 Vyvanse Vyvgart Hytrulo WAC gene WARN WARN filing WARN notice WEE1 WEE1 inhibitor WHIM syndrome WP1066 WRN inhibitor WVE-N531 Wakefulness Test Walgreens Boots Alliance Walmart partnership Waltham lab Waltz Health War-Lock platform Warm autoimmune hemolytic anemia Warning Letter Warsaw-Duchnice Washington pushback BioSecure Act COINS Act 2025 John Moolenaar Myers Squibb Hengrui Pharma Wuxi AppTec Washington state Waterfall Scientific Waukegan WeDosify Wearable Behavior Model Wearable Electronic Devices Wearable biosensors Weave Bio Web Site Wegovy tablets Wehr Wehr site closure Weight Watchers Weldon Weldon 's Welfare Werewolf Therapeutics Werner Syndrome Werner helicase Werner helicase inhibitor Westborough Massachusetts Western biotech Westlake University Wet AMD Wet Age-Related Macular Degeneration White House liaison Whitestown William Blair Wilmington Windward Bio With configuration Withdrawal Symptoms Wolfgang Wienand Wolters Kluwer Health survey Women Wonderbelly Workforce Working Group World WorldMeds Wounds - qualifier Written - Consent Mode WuXi Biologics' Wuhu X-Cell X-Linked XEN1101 XHANCE XOMA XOMA Royalty XPro XR Xaira Therapeutics Xanthomatosis Xarelto Xarelto patent Xencor Xenograft procedure Xenon Pharmaceuticals Xenon Pharmaceuticals ' Xevinapant Xianweiying Xilio Xinjiang Xolremdi Xpress Wellness Xspray Pharma XtalPi Y Combinator Y-mAbs Y220C mutation YARW YUVEZZI Yervoy Yidafan Yngvi Bio YolBE YolCas Yosemite Young Young Adult Young Talent Yvonne Greenstreet Z-1018 ZAIDYN ZBPro Diagnostic v2.0 ZBeats ZENEO® ZENITH trial ZEPHYR Phase 2 ZEPIZURE ZG006 ZI-MA4 ZIMA-101 ZM-02 ZUSDURI ZW171 Zaka Zami Aberman Zanidatamab Zanvastro Zelgen Zelis Zelluna Zellweger Syndrome Zemaira ZenGUARD Zenbexus Zentalis Zentek Zepbound KwikPen Zephyr AI Zervimesine Zhongmou Zifo Zilebesiran Zilovertamab Zinc Fingers Zokinvy Zongertinib Zonsen PepLib Zoë Zuellig Pharma ZyDoc a year later aDBS aGvHD aTyr abdakibart abelacimab acasunlimab accelerating development accelerator acceptance access strategy accessible accretion accumulation aceclidine acquisition talks acquisition termination active pharmaceutical ingredients activin A activin signaling acute graft acute heart attack acute mania acute optic neuritis acute systemic infection acute treatment ad spending adaptive deep brain stimulation adaptive dosing adcomm adeczibart adjunctive therapy adjunctive treatment adjuvant Tecentriq adjuvant setting adjuvant treatment administration time administrative law administrative proceedings advanced manufacturing advanced solid malignancies advanced sqNSCLC advanced therapeutics advisers advisory advisory appointments advisory meetings advisory panels aesthetic treatments affairs affinity maturation agazisiran age 2 age restriction age-related diseases agency departures agency instability agency staffing shortages agentic AI platform aggregator agile agilon aging reprogramming aging-related diseases aglatimagene agreement rate ai3Bio alanyl-glutamyl-aspartyl-glycine aleniglipron all-cash tender all-stock merger allergic diseases alliance allogeneic cell therapy allogeneic hematopoietic stem cell transplant with purging allosteric drugs alpha opportunities alpha radioligand therapies alpha radiopharmaceutical alpha-1 antitrypsin deficiency-associated lung disease alpha-Mannosidosis alpha-synuclein antibody alternative testing alternatives aluminum potassium sulfate ambulatory care services ametefgene parvec amezalpat amplitude-integrated EEG amsacrine/azacitidine/etoposide amyloid beta antibody amyloid-beta amyloid-lowering drug analogy anifrolumab anitocabtagene autoleucel annamycin annualized annualized height velocity anti-APRIL antibody anti-CD3 antibody anti-CD47 monoclonal antibody anti-EGFR anti-PD-1 anti-TSHR anti-TSLP antibody anti-VEGF therapy anti-aging anti-amyloid antibody anti-amyloid drugs anti-amyloid therapies anti-vaccine movement antibody candidates antibody collaboration antibody design antibody discovery antibody humanization antibody reactome antibody therapeutics antibody-chopping drug antibody-targeted antisemitism antisense antithrombin III antitrust litigation antitrust probe antitrust review antitrust scrutiny antitrust verdict anvumetostat apalutamide apazunersen apecotrep apical plasma membrane urothelial plaque apomorphine hydrochloride applicability application assessment appropriations approval status approval sweetener apremilast arcotatug argenx Vyvgart aroxybutynin artemether-lumefantrine artificial dyes artificial luciferases ascension aseptic fill-finish aseptic manufacturing asset acquisition asset purchase agreement asset termination assumes assurance asthma approval at-home at-home colon cancer at-home screening ataluren atlases atomoxetine attraction attractiveness auction autoimmune drugs autoimmune health autologous cell therapy autologous neurons automated bioanalysis automated biology autonomous avibactam avutometinib plus axon degeneration axonal degeneration azetukalner aztreonam b.well partnership backer bacterial detection baldness cure bankruptcy auction bankruptcy filing basal insulin basel becton dickinson belumosudil belzutifan bemarituzumab bempikibart benefit-risk benefit-risk profile benralizumab berahyaluronidase alfa berobenatide bespoke best-in-class efficacy beta version betovumeline bexmarilimab bictegravir bidders bile acid therapy biliary cholangitis billing practices bimagrumab bimatoprost IOL bimekizumab binding affinity measurement biochemical recurrence biodefense bioequivalence bioequivalence facility bioequivalence study bioequivalence testing biofilm-driven chronic respiratory disease biologic blockbusters biomanufacturing jobs biomarker qualification biomarker test biomedical foundation models biomedical innovation biometric tracking biomolecular AI biomolecular structure prediction biopharma agents biopharma commercialization biopharma exit strategy biopharma fund biopharma industry biopharma job biopharma jobs biopharma layoffs Q2 biopharma regulation biopharma startups biopharma survey biopharma venture biopharmaceutical partnership biopharmaceutical sector biopharmaceutical startups biopreservation bioprocess biosimilar competition biosimilar guidance biosimilar medicines biosimilarity biosimilars approval biotech AI biotech IPOs biotech careers biotech closure biotech collaborations biotech crackdown biotech dealmaking biotech employment biotech executive biotech finance biotech financing biotech incubator biotech investors biotech leadership biotech licensing biotech pivot biotech spinoff biotech strategy biotech workforce biotechnology innovation biotechnology layoffs biotechnology partnerships biotechnology services biotechnology stocks bioweapons worries bipartisan criticism bipolar I bird flu vaccine birtamimab birth dose bispecific bispecific T cell engager bispecific antibody screening bispecific antibody technology bispecific competition bispecific failure bisretinoid black-box warning bleomycin/dacarbazine/lomustine/vincristine blockbuster autoimmune blockbuster drug blockbuster sales blocker blood biomarker test blood biomarkers blood clotting drug blood pressure ambulatory blood pressure medication blood pressure pill blood vessel disorders blood-based biomarkers blood-based cancer board members board nomination board restructuring body proportionality bofanglutide bolt-on bone lesion prevention bonus boom boost booth bortezomib brain drug delivery brain fluid brain organoids brain shuttles brain volume brain-penetrant brain-penetrant delivery brand-name brand-name drugs brand-name prescriptions branded medicines brelovitug brengitecan bridging study briefing briefing documents brimonidine broaden bulks list bullishness business development priority business options business plan business practices business split business strategy business unit butyrophilin superfamily buying spree cAMPfield cDNA display proteolysis cGAS inhibitor cGVHD cUTI cUTIs cabotegravir cagrilintide calcific aortic valve stenosis calcium camlipixant campaign campaigns campus relocation camrelizumab canakinumab cancellations cancer antigen therapy cancer biotech cancer blood test cancer combination therapies cancer diagnostics cancer drug sales cancer drug trials cancer funding cancer intelligence cancer medicines cancer meds cancer prediction cancer proteins cancer research trends cancer testing cancer therapeutics cancer treatments cancer trials capacity management capacity quadruple capital constraints capital investment capivasertib capivasertib PIK3CA AKT pathway capsid delivery capsid delivery platform car-treg cell therapy carbachol cardiac imaging cardiac myosin inhibitor cardiac remodeling cardiac research cardiac safety cardiac safety signal cardiac sarcomere modulator cardiac signals cardioendocrine diseases cardiometabolic care cardiopulmonary complications cardiorenal medicine cardiotoxicity screening cardiovascular asset cardiovascular benefits cardiovascular conditions cardiovascular deaths cardiovascular gene therapy cardiovascular inflammation cardiovascular program cardiovascular safety cardiovascular screening cardiovascular trial care coordination career cargo receptor ligand activity cartilage degradation carve-out casdatifan case accrual cash balance cash dividend cash payment cash-paying cccDNA cell analysis cell classification cell q cell therapy sale cell therapy sales cell transfer cell transformation cell-associated neurotoxicity cell-cell project cell-device combo cell/gene therapy cellular perturbation cellular rejuvenation cema-cel cemdisiran central reads central subfield cerebrotendinous xanthomatosis cfNI software chairman resignation charmed chase checkpoint inhibitor-resistant chemical alternatives chemical modifications chemical space chemo-displacement chemo-turned-gel drug chemotherapy-free regimen chenodeoxycholic acid childhood health chinese medicine chlorodihydroxypyridine/potassium oxonate/tegafur cholesterol ester transfer protein inhibitor cholesterol-lowering choline chronic disease epidemic chronic disease management chronic graft-versus-host disease chronic health conditions chronic hepatitis delta virus chronic thyroid eye disease cilta-cel ciltacabtagene autoleucel cisplatin-eligible cisplatin-ineligible citizen petition cityRNA civil clawback rate clazakizumab clean sweep clear-cell RCC cleavage-inducing tiny RNAs clemidsogene lanparvovec cleminorexton click clinic entry clinical dataset clinical diagnostics clinical documentation clinical failures clinical holds clinical improvement clinical intelligence clinical interoperability clinical proof-of-concept clinical queries clinical reproducibility clinical research services clinical results clinical seizure clinical terminology clinical trial conduct clinical trial halt clinical trial oversight clinical trial pathway clinical trial results clinical trial review clinical trial safety clinical trial update clinical update clinical utility clinical validity clinical visualization clinical worsening clinical-stage AI startups clinical-stage biopharma clinical-stage biopharmaceutical clinical-stage biotech clinical-stage biotechnology company clinical-stage company clinical-stage immunotherapy clinical-stage oncology pipeline clinical-stage pharmaceutical clinical-trial automation clinical-trial data clinical-trial setbacks clinically meaningful clinicogenomics cliramitug clofutriben clone stability closed-loop interventions closed-loop systems closed-system automation cloud providers co-development co-exclusive license co-location coalition cognition cognitive improvement cognitive side effects collaborative framework collaborative healthcare coloplast colorectal contender commercial supply chain commissioner confirmation commitment commitment unchanged commitments community grants community sites community-oriented clinical trials company closure company transformation compensation pharma compensation reform competition codenames competition rules competitive intelligence competitive weight loss medication complement system complement-mediated disease complete response rate complete responses complete-response rate composition-of-matter patent compounding pharmacy computational drug discovery computational pathology computational power computational protein design computational protocol concealment concerns safety concessions conditional approval pathway conditioning regimens confident confidentiality confirmation hearing confirmatory study confirmatory study failure conflict of conservative criticism conspiracy constitutional challenge constitutionality consumables consumer relationship content intelligence contextual errors contingent value continuous continuous trial contract cancellation contract extension contract manufacturer contract research controllable controlled-rate freezing controversy conversation conversational AI conversion factor convertible convertible loans cooperation copper histidinate copper isotopes core vaccines corn starch cornea surgeon corneal endothelial disease coronary imaging coronary trial corporate development cortisol modulator cost of care cost reduction cost-cutting initiatives cost-effective cost-effectiveness cost-effectiveness ratios cost-reduction cost-saving country-of-origin labeling covalent binding drugs covalent biologics covalent chemistry covalent drug discovery cranial neurosurgery crash craving control credit card fees critical bleeding crizanlizumab crofelemer cross-border investment cross-border pharma cryopreserved leukapheresis crystallographic data ctDNA-guided therapy curated data curative medicines curative potential customer-facing organization customs loophole cut corners cutaneous disease activity cutaneous remission cyclic AMP cyclic adenosine-5'-trimetaphosphate cyclobenzaprine cynicism cytarabine/etoposide/methotrexate protocol cytisine dCas9 daily pills daisy danegaptide dapagliflozin daratumumab daridorexant data bottlenecks data breach data gaps data generation data harmonization data misinterpretation data modernization data package data secrecy data solutions data stewardship data stolen data-driven decisions data-driven health data-driven innovation daxdilimab de novo miniproteins deal activity deal termination death risk reduction debt maturity extension debt obligations decade-long safety test deceptive deceptive marketing decision day decision science declaratory judgment defactinib deficiencies degrader degree of relationship - exchange delayed readout delgocitinib delist delivery options demerger demyelination dencatistat denecimig depression drug deprioritization deputy commissioner deruxtecan-nxki deucrictibant XR developmental restoration device regulation dexmedetomidine diabetes drugs diagnostic kit diagnostics industry diazoxide choline difficult-to-treat psoriasis digestive health startup digital coaching digital cognitive assessments digital dermatology digital enablement digital endpoints digital health ecosystem digital health records digital health regulation digital health screener digital infrastructure digital marketing digital medicine digital microfluidics digital pathology prognostic test digital quality systems digital solutions digital therapeutic digital tools digital twin diluted cardiomyopathy dimethylethylsilylimidazole direct-to-consumer ( DTC ) direct-to-patient model director director firing directors disability services disciplined discounts discovery engine discovery market disease activity disease awareness disease clinical trials disease control rate disease drug disease flexibility disease program disease research disease sales disease therapies disease treatment disease vouchers disease-modifying treatment disorder control (procedure) disordered proteins disparagement dissolvable distributor network divestiture divestitures domestic pharmaceutical industry domestic production domestic supply chain dopamine doravirine doravirine/islatravir dose-response dotatate doubt downsides downsizing downturn draft report drinking levels drug activity drug ads drug affordability drug application drug approval outlook drug candidates drug collaboration drug combo drug competition drug conjugates drug delivery innovation drug delivery platform drug developability drug development pipeline drug development sentiment drug discontinuation drug discount program drug establishment registration drug failure drug import duties drug import plan drug importation drug imports drug ingredients drug innovation drug lag drug launch drug licensing drug manufacturers drug markups drug optimization drug price discounts drug price negotiation drug prices fall abroad drug pricing plan drug pricing policy drug production drug quality drug rebates drug rejection letters drug rejections drug relabeling drug review reforms drug reviews drug sales drug supply chain drug trial setbacks drug-development candidates drug-device drug-resistant drug-resistant TB drug-resistant focal seizures drug-substance drug-to-data pivot drug-trial dual pathway inhibition dual-agonist dual-payload ADC dual-payload technology dual-targeting dulaglutide duplicate discounts dwarfism trial e-Lung e-posters eGenesis eRNA earlier-line treatment early disease early-phase trials early-stage trial earnings beat easing ecnoglutide efdoralprin alfa efimosfermin alfa efzofitimod egg-based elacestrant elebsiran electronic health record - ActClassContainer elenestinib elinzanetant elironrasib elranatamab emergency medicine (field) emiltatug ledadotin emotional dependency employee layoffs employment employment reduction enLIGHTEN Discovery Platform end-to-end antibody discovery endocrine disease specialist endpoint selection enforcement action enforcement letters enfortumab enfortumab vedotin engasertib engineered peptides enlicitide decanoate enobosarm enrollment forms enrolment ensifentrine ensitrelvir entera enterprise reorganization environmental enzymatic enzyme engineering enzyme restoration enzyme technology eosinophil epigenetic immunomodifier epigenetic modulator epigenetic therapy epinephrine eplerenone equity buyback equity financing equity line equity upside ersodetug escape velocity esreboxetine estate estrogens etalanetug etanercept etisparvovec etisparvovec-hopf etrolizumab evaluation event cycle everolimus evidence-based exagamglogene autotemcel exclusivity extension executive actions executive chair executive changes executive compensation executive exits executive survey executive team executive vice president existential threats expanded label expansions expedited pathway experts booted expirations exploitation external control group external controls external partnerships extrahepatic RNAi eye disease trial eye treatment facilities facility closure facility consolidation factor XIIa factory closure fam-trastuzumab fantasy-romance farabursen farm-to-hospital faster fat loss fat reduction federal AI federal agencies federal courts federal directives federal grants federal workers fee structure fentanyl fesoterodine fibroblast immunology fibrodysplasia fibrosing fibrotic diseases fidrisertib field ablation figures filing checklist final analysis financial compliance financial guidance suspension financial outlook financial recovery financial strategy financial struggles financial troubles financing strategy findings aspects finerenone firi-cel firing first-half first-in-class antibiotic first-in-class drugs first-line maintenance fiscal five-year five-year follow-up flagship office flaws flu/COVID-19 focal seizures foreclosure proceedings foreign companies foreign direct investment foreign drug manufacturing foreign factories foreign investment formula update formulary exclusion formulation viscosity formulations four-letter suffix franchise frataxin frataxin protein fratricide-resistant free trial frontline AML frontline therapy front‑line treatment fruit-flavored vapes full-year guidance full-year sales fulvestrant fumaric acid function functional testing funding agreement funding bill funding cut funding environment funding lapse funding round funding rounds fungal prophylaxis furosemide future-proofing gRED gallium gamma secretase inhibitor gamma-linolenic acid garadacimab-gxii garetosmab-grts gastric inhibitory polypeptide receptor gastroenteropancreatic neuroendocrine tumors gastrointestinal gemcitabine intravesical system gemcitabine releasing system gene delivery process gene editing trial gene editor gene modulation gene synthesis gene therapy platforms gene variants gene writing gene-editing therapy gene-silencing general-purpose generative generative design generative models generic competition generic manufacturing generic medications generic semaglutide generic tirzepatide generics revenue generics slump genetic cell genetic diagnosis genetic dilated cardiomyopathy genetic epilepsies genital lesion reduction genome engineering genome screening genomic analysis genomic drug discovery genomic medicines genomics AI genotoxicity geographic population geopolitical factors geopolitical risk glatiramer acetate global approval global commercialization global commercialization rights global competition global competitiveness global drug development global drug pipeline global growth strategy global headquarters global health programs global health security global license agreement global net sales global network global price global research collaboration global sales global strategic R&D center global strategic collaboration global strategic partnership global strategy global trade tensions global trial global workforce reduction glucose glycoengineering glycosylation go-to-market models golden decade golimumab golukibart government events government programs government review governmental engagement grace granite grant cancellation graph neural networks green energy green list green manufacturing gross profit growth Z-score growth drivers growth opportunities growth products guidance raise guidance revision guidance upgrade guidances gusacitinib hair loss treatment halt hand sensation hands-free harassment head-to-head psoriasis head-to-head trial headcount health coverage health data privacy health industry health information health officials health prediction health records health system partnerships health systems health tech venture health tracking health workers healthcare IPO healthcare IT healthcare agencies healthcare analytics healthcare appointments healthcare artificial intelligence healthcare benchmark healthcare budget healthcare changes healthcare data healthcare executive healthcare finance healthcare financial performance healthcare funding healthcare infrastructure healthcare innovation healthcare interoperability healthcare legislation healthcare marketing trends healthcare operational healthcare operations healthcare payments healthcare specialist healthcare spending healthcare startup healthcare trends healthcare venture healthcare workflow healthspan healthy lifespan healthy longevity heart drug heart events heart risk-benefit debate guidelines heavy drinking height velocity hematologic cancers hematologic care hematoxylin and eosin ( H&E ) stained hemophilia A program hep C pill hepatitis B functional cure hepatitis B policy change heroin herpesvirus 2, human heterozygous high-dose high-dose neurotherapy high-dose regimen high-performance computing high-profile high-risk patients high-throughput higher risk higher-value reagents highest-paid pharmaceutical CEOs hindrance hiring challenges hiring rebound histologic remission hold-and-kill homegrown hormone receptor-positive hospital apps hospital base hospital intervention hospital nutrition hospital operations host disease hpDNA https://lnkd.in/gYKjeQ3n human care navigators human-relevant models huntingtin-lowering hyaluronidase hyaluronidase, human recombinant hybrid intelligence hydroxyurea hyper-personalized engagement hyperscaled data iMTP iNHL iPSC-derived iPSCs iSCIB1 + iSCIB1 + melanoma immunotherapy icatyde idiopathic Parkinson 's disease ifosfamide illegal immigration iloperidone iluzanebart image management imaging AI imaging biomarker immune compromise immune disorder therapy immune mapping immune profiling immune protection immune reset immune signaling pathways immune system reprogramming immune-based cancer cell therapies immune-related adverse events immuno-dermatology immuno-fibrosis immunocytokine immunoglobulin G immunology drug development immunotherapy drugs implantable device implementing import rules import taxes impression (attitude) impurity in situ in vivo studies in vivo therapy in-office inaxaplin incidents inclacumab incretin secretagogue incretin therapy indictment individual choice individual-based decision-making induction trials ineffective efforts infant infestation influenza prevention information session inhaled drugs inhaled lung disease inhaled therapies inidascamine initiation protocol injectable obesity therapy injectables innovate innovation centre innovation grants innovation pipeline innovation strategy innovative drugs innovative trial inorganic pyrophosphate inpatient insider insider trading insolvency insulin delivery insulin efsitora insulin icodec-abae insulin production insulin resistance trends integrated decision-making integrated solutions interferon pathway interleukin-11 interleukin-23 receptor activity interleukin-3 interleukin-4 intermediate-risk internal disagreement internal rate internal tensions international drug international drug benchmarks international operations international pricing international reference pricing international trade internet phrase internship intestinal growth intisemeran intra-abdominal infections intracortical microstimulation intraoperative guidance intrathecal delivery intrathecal formulation intravenous delivery intravenous formula investigator-initiated trials investment cutback investment grants investor appetite investor reaction investor rescue investor scrutiny investor sentiment ion channel program irAE isatuximab isolator technology issuance itolizumab itraconazole ixekizumab ixovec iza-bren izalontamab judgment jumping gene jumping genes juniper tar jurisdiction jury kickback scheme kidney drug kidney therapeutics kilobase pairs kinase inhibitor [EPC] kininogenase knockoffs kynurenic acid kyron.bio lab results label extension label update labeling change labeling changes laboratory modernization laboratory reform programme lack of lack of transparency lackluster data lanifibranor large-scale manufacture laromestrocel late recurrence risk late-stage assets late-stage clinical development late-stage pipeline late-stage testing launch expenses launch sequencing lawmakers layoff leaders leadership shake-up league lean muscle lecanemab-irmb legacy cancer legacy operations legal concerns legal victory legality lenacapavir weekly lenalidomide lender takeover lentiviral vectors letrozole leuprolide levacetylleucine levodopa levosimendan levy liability frameworks license suspension licensing dispute licensing restrictions lidERA life science incubator life sciences companies life sciences fund life sciences real estate life-extension life-saving medicine lifonebart likeability lincomycin linezolid liquidation lirafugratinib live event liver enzyme elevation liver mRNA medicine liver safety liver survival loan financing localization locally advanced locally advanced head locally advanced risk long-acting injectable long-acting protection long-acting therapies long-acting therapy long-term care longevity science lorlatinib loss of function loss treatment lotiglipron low low-cost lower dose lower-risk myelodysplastic syndromes lunbotinib fumarate lung scarring lunsekimig lupus skin drug lurbinectedin lutetium lymph nodes lymphocyte immune globulin, anti-thymocyte globulin lymphocyte-activation gene 3 protein lymphocyte-activation gene 3 protein, human mAbxience mCSPC mCombriax mFARS mFlusiva mGnP mHSPC mNEXSPIKE mRESVIA mRNA contracts mRNA degrader mRNA misinformation mRNA production mRNA therapy mRNA-1083 mRNA-1283 mRNA-1647 cytomegalovirus vaccine mRNA-4359 mRNA-based mRNA-based Personalized Cancer Vaccine mRNA-4157 mRNAs mTNBC mTORC1/2 inhibitor machine learning model macrocycles macrocyclic drugs macroeconomic macrophage-based programmes macular maintenance phase malignancy risk malignant haematology management layers management technique mandates manifestation manufacturing challenges manufacturing closure manufacturing company manufacturing consolidation manufacturing jobs manufacturing license manufacturing organization manufacturing practice manufacturing problems manufacturing process manufacturing shutdown manufacturing uncertainty maridebart cafraglutide marketing approval marketing approval milestones marketing authorisation marketing officer marketplace marstacimab mast cell therapy match Eylea maternal-fetal monitoring mazdutide measles, mumps, rubella, varicella vaccine measurable outcomes mechanistic trials mechanoporation med-tech median employee medical advancements medical affairs reputation medical benchmarks medical breakthroughs medical data medical device company medical documentation AI medical freedom medical groups medical jargon medical leadership medical loss ratio medical review medical spas medical supplies medical supply chain medical technology exemptions medical wearables medical-device AI medtech industry meeting cancellation mega depots megadeal megascale melanin-concentrating hormone member membranoproliferative glomerulonephritis men 's health menen inhibitor mental health innovation mepolizumab merger cancellation merger termination mesothelin metabolic dysfunction-associated steatohepatitis metabolic medicines metagenomic sequencing metastasis-free metastatic solid tumors metastatic triple-negative breast cancer mezigdomide mezigitamab mice studies microcystic lymphatic malformations microdosing microneedle patches microneedles microparticle technology microservices mid-2030s mid-stage middle dose middle-income countries middlemen midline glioma midterm migraine prevention milestone payment milsaperidone mini-proteins miniPDX minimis exemption minimization miniprotein design suite mirror peptides missed doses missed milestone mitazalimab miv-cel mivelsiran modular modular integrase platform molecular AI molecular design molecular entities molecular glue degrader molecular modalities molecular point-of-care moments monogenic kidney diseases month most-favored motor fluctuations motor milestones mouse models movers mucosal healing multi-agent system multi-agent systems multi-agonists multi-cancer screening multi-cancer tests multi-domain proteins multi-institutional research multi-medicine platforms multi-modal multi-omic strategies multi-payload multi-program collaboration multi-sensor multi-specific antibodies multi-target collaboration multi-year collaboration multibillion-dollar market multiforme multimodal approach multimodal data multiple disease areas multiplex test multiport surgery multispecific antibody muscle disease therapy muscle health muscle loss muscle mass muscle strength endpoint muscle-invasive musculoskeletal conditions mutation testing myQA StarTrack myelin repair myosin inhibitor myostatin antibody myostatin inhibitor nAMD nChroma Bio nGen platform nHCM naloxegol naltrexone-bupropion naming convention nano-in-micro delivery nanobody nanodelivery nanosecond naproxen-n-butyl nitrate narcolepsy drug narrow sales narsoplimab natalizumab nation policy national dementia registry national priorities national priority review voucher national priority review vouchers national sector growth nations natural orifice surgery naturalX nature-inspired drug discovery navacaprant navenibart navtemadlin needle-free vaccines negative adcomm negative opinion negotiators nemolizumab neo-epitope cancer vaccine neoantigen therapy neon neosubstrate neuro injury neuro pipeline neuro-metabolic diseases neuro-rare diseases neuro-specialty diseases neurobehavioral symptoms neurodegeneration therapy neurodegenerative neurofibroma neuroimmune disorders neuroinflammatory neurological imaging neurological therapies neuropathic corneal pain neuroplastogens neuroprotective neuropsychiatric adverse events neuropsychiatric disorders neuropsychiatric drugs neuroreparative therapeutics neuroscience division neuroscience portfolio neurotechnology neurovascular AI neutrophil-mediated disease new product newco nexiguran nexiguran ziclumeran next generation viral vectors next-gen brain therapies next-gen pneumonia next-generation Covid vaccine next-generation RNAi next-generation drugs next-generation vaccine nimodipine nintedanib ninth nipocalimab-aahu nirsevimab nizubaglustat nmHSPC nodularis nomination committee non-European ancestry non-FDA non-antipsychotic non-competitive profile non-cystic fibrosis bronchiectasis non-dilutive non-dilutive financing non-dilutive funding non-generic specialty non-hormonal therapy non-incretin non-incretin therapies non-incretin therapy non-inferiority non-mRNA vaccine non-metastatic non-opioid non-opioid pain drug non-opioid pain medication non-opioid pain relief non-opioid pain therapies non-relapsing secondary progressive non-surgical back pain non-ultrasound-trained operators noncirrhotic nonclinical reporting nonprofit webinars nonrelapsing nonresponder nonsurgical treatment options normative wakefulness nucleic acid delivery nusinersen obesity pipeline obesity therapy obesity-related cancers obsidian ocadusertib ocular adverse events ocular delivery ocular immunology offerings office closure offloading offshore older children oligomer selectivity olorofim olverembatinib omnichannel on-demand once-daily pill once-daily tablet once-yearly oncology acquisition oncology advancements oncology collaboration oncology combo oncology company oncology decisions oncology diagnostics oncology ecosystem oncology expert oncology licensing deal oncology market oncology overlap oncology pivot oncology portfolio oncology studies oncology supply oncology therapeutics oncology trials oncolytic immunotherapy online Laboratory Animal Science MS online program online sellers ontunisertib onvuzosiran open innovation open science open-label extension open-source AI open-source dataset openFDA operating costs operating expenses operating profit margin operational efficiency operational transformation opportunities optimisation programme opto-acoustic imaging oral FASN oral PCSK9 oral asthma therapy oral biologics oral carbapenem oral cholesterol pill oral formulations oral hair loss oral inhibitors oral minoxidil oral obesity oral obesity drug oral peptide oral pill oral pill vaccine oral presentation oral regimen oral small molecule RNA degrader oral small-molecule therapeutics oral small-molecule therapy oral targeted therapy oral weight loss drug orbital manufacturing orchestration orelabrtuinib orexin agonist orexin receptor type 2 orexin-2 receptor agonist organ donor organ fibrosis organ transplant rejection organic growth organizational simplification orglipron orphan drug exclusion orphan medicine orthopedic innovation osavampator osimertinib ossificans otoferlin out-licensing outbound investment over-reaction overall response rate overhangs overhaul overhype overmedicalization overseas oversubscribed oversubscribed fund ownership increase ozekibart ozureprubart p-tau217 p53 reactivator pM category pTau217 packaging issues pain assets pain crises palazestrant palivizumab pamirtecan pan-JAK inhibitor pan-KRAS pan-TEAD inhibitor pandemic influenza paradigm parent parental choice partial response partnering with pasritamig patent expiration patent license pathology AI patient definition patient intake patient management patient meals patient navigation patient populations patient recruitment patient-provider interaction patient-specific therapies patient-specific therapy patient-ventilator asynchrony patritumab pattern hair loss pause recommendation pay-for-delay payer paying payload payors peak sales pediatric brain cancer pediatric diseases pediatric dosage pediatric drug designation peer pelareorep penicillin recall pent-up demand peptide therapeutics peptide therapy performers perioperative therapy permanent role personal data personal genome service personalized cancer therapy personalized care personalized health services personalized healthcare personalized neuromodulation personalized treatment personnel change perspectives pertuzumab petition pharma TV ads pharma biggest company pharma brand engagement pharma companies pharma consolidation pharma directors pharma division pharma industry pharma investment pharma investments pharma marketing pharma packaging pharma patent expirations pharma policy pharma reforms pharma reshoring pharma response pharma silos pharma skills shortage pharma tech pharma trade group pharmaceutical AI pharmaceutical advertising crackdown pharmaceutical backing pharmaceutical collaboration pharmaceutical communications pharmaceutical delays pharmaceutical delivery pharmaceutical divestment pharmaceutical drug discount resistance pharmaceutical earnings pharmaceutical employment pharmaceutical imports pharmaceutical investment pharmaceutical investment Germany pharmaceutical lawsuits pharmaceutical leadership pharmaceutical licensing pharmaceutical lobby pharmaceutical market pharmaceutical megadeal pharmaceutical mergers pharmaceutical milestones pharmaceutical processing pharmaceutical rebates pharmaceutical revenue pharmaceutical sector pharmaceutical setback pharmaceutical setbacks pharmaceutical survey pharmaceutical trade pharmaceutical trade war pharmacy platform pharmacy reimbursement phase 2/3 trial phase 3 POIESIS trial phase 3 failure philanthropy phosphodiesterase 4B phosphorylated physiologic rate physiological aspects physiological chemistry pilot data pimecrolimus pipeline blips pipeline cull pipeline disruptions pipeline gaps pipeline management pipeline restructuring pipeline setbacks pipeline shake-up pipeline shift pipeline update pipeline work pivekimab sunirine pivot resources pivoxil pizuglanstat placebo-adjusted efficacy placebo-adjusted improvement plant construction plasma-derived therapies plasma-derived therapy platelet levels platform immunotherapy * * pledge plozasiran pneumococcal conjugate vaccines pociredir podcast political politicization poly-refractory rheumatoid arthritis portfolio companies portfolio prioritization portfolio reprioritization portfolio support porustobart posdinemab post-COVID post-hoc analysis post-marketing requirement post-marketing studies post-thaw viability postprandial povetacicept pozdeutinurad practice expense practice-changing pre-IPO pre-IPO ' pre-commercialization pre-seed funding precision cardiology precision neurology preclinical CRO preclinical assets preclinical drug preclinical drug discovery preclinical pancreatic cancer preclinical program preclinical studies preclinical testing pregnancy detection pregnancy screening preliminary assessment preliminary injunction premium hikes prescriber prescribers prescribing habits prescribing rules prescription drug ads prescription renewals prescription-drug prices prespecified pretomanid prevention antibody preventive healthcare preventive services panel price controls price decline price drop price hike price transparency price-fixing pricing flaw pricing information pricing policies pricing practices pricing pressures pricing reform prifemilast primary endpoints primary listing princeton prion disease program prioritization priority brands priority vouchers private block trade private placement financing proactive care producer cell lines product hopping product strategy production relocation professional development profit profit margin profit-sharing profitability programmable RNA medicines programmable biology progressiva project cancellation proof-of-concept study propane propiolactone proprietary data protections protein AI protein compounds protein drug discovery protein elimination therapeutics protein expression protein expression platform protein folding protein levels protein science protein structures protein-based vaccine protein-ligand datasets protein-ligand prediction provider operations provider training provisional patent prula-cel pruritus chronic pruritus treatment pseudobulbar psychedelic biotech psychedelic medicines psychedelic mental health market psychedelic supply psychedelics guidance psychiatric trials psychiatry pipeline public biotech public companies public company public fund public health agencies public health crisis public health debate public health guidance public health leaders public servants pulmonary disease spinoff pulsed field ablation pure-play strategy qAF quality assurance quality control quality control violations quantitative EEG quantitative autofluorescence quantum phenomena quarterly sales radiation-free imaging radical transparency radiographic remission radioisotope facility radioisotope supply chain radiological imaging radiology pathology radiotheranostics radiotherapeutic radiprodil ransomware rare blood disorder rare disease rare-disease clinical trials rates reimbursement ravulizumab reSET (device) readout real-estate real-time real-time clinical trials real-time disclosure real-time publishing realistic medical scenarios rebate rate rebate schemes rebates rebrand rebranding reciprocal tariffs recognition recombinational repair record sales recruitment recurrent astrocytoma redesable eye drop reduce reduction in force reentry capsules reform refractory large B-cell lymphoma refractory myeloma refusal-to-file regenerative cell therapy regional episode registrational registrational study registrational trial regulatory AI frameworks regulatory RNA regulatory advocacy regulatory agency regulatory alignment regulatory barriers regulatory certainty regulatory change regulatory changes regulatory complexity regulatory concerns regulatory consulting regulatory decision regulatory disclosure regulatory dynamics regulatory easing regulatory flexibility regulatory governance regulatory harmonization regulatory hurdle regulatory innovation regulatory law regulatory meetings regulatory oversight regulatory reforms

Show more Show less

Powered by Blogger

X-Data LLC